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EVALUATING THE EFFECTS OF AROCLOR 1260 IN NON-ALCOHOLIC 
FATTY LIVER DISEASE: THE ROLE OF XENOBIOTIC RECEPTORS 
 
Banrida Wahlang 
November 17, 2014 
 
Polychlorinated biphenyls (PCBs) are persistent environmental toxicants, 
present in 100% of US adults and dose-dependently associated with non-
alcoholic fatty liver disease (NAFLD) in epidemiologic studies. PCBs are 
predicted to interact with receptors previously implicated in xenobiotic/energy 
metabolism and NAFLD. These receptors include the aryl hydrocarbon receptor 
(AhR), pregnane xenobiotic receptor (PXR), constitutive androstane receptor 
(CAR), peroxisome proliferator-activated receptors (PPARs), liver-X-receptor and 
farnesoid-X-receptor.  
This study evaluated the hepatic effects of the PCB mixture, Aroclor 1260, 
whose composition mimics human bioaccumulation patterns, in a mouse model 
of diet-induced obesity. Male C57Bl/6J mice were fed a control or 42% high fat 
diet (HFD) and exposed to Aroclor 1260 (20 or 200 mg/kg in corn oil) for 12 
weeks. Aroclor 1260 exposure was associated with decreased body fat in HFD-
v 
 
fed mice. Aroclor 1260+HFD co-exposed mice demonstrated increased 
inflammatory foci at both doses while serum cytokines and hepatic expression of 
IL-6 and TNFα were increased only at 20 mg/kg. Aroclor 1260 induced hepatic 
Cyp3a11 (PXR target) and Cyp2b10 (CAR target) expression but Cyp2b10 
inducibility was diminished with HFD-feeding. Cyp1a2 (AhR target) was induced 
only at 200 mg/kg.  
In PXR-/- and CAR-/- mice, Aroclor 1260 exposure resulted in 
steatohepatitis with increased basal hepatic TNFα and IL-6 expression. PXR-/- 
mice had increased % body fat and liver to body weight ratio regardless of 
exposure. HOMA-IR decreased in all groups following Aroclor 1260 exposure. 
PXR-/- mice exposed to Aroclor 1260 showed impaired glucose uptake, increased 
hepatic gluconeogenic and lipogenic gene expression. The knockout groups 
demonstrated increased basal mTOR1 activity while Aroclor 1260 exposure 
increased AMPKα activity. Thus, PXR and CAR participate in hepatic energy 
metabolism and are protective in Aroclor 1260-induced liver injury. 
The study further evaluated Aroclor 1260 and selected congeners as 
potential ligands for human receptors utilizing HepG2 and COS-1 cell lines; and 
primary human hepatocytes. The results suggested that Aroclor 1260 is a human 
AhR, PXR and CAR3 agonist, a mixed agonist/antagonist for CAR2 and an 
antagonist for human PPARα. 
In summary, Aroclor 1260 worsened hepatic inflammation in diet-induced 
obesity. HFD decreased the protective CAR/PXR activation illustrating the 
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Figure 5.1. Environmentally-relevant PCB-diet interactions mediate the transition 





Polychlorinated biphenyls (PCBs) 
Polychlorinated biphenyls (PCBs) are polyhalogenated aromatic 
hydrocarbons consisting of up to 10 chlorine atoms attached to a biphenyl group. 
Depending on the number of chlorine atom substituents, there are 209 individual 
PCB congeners that are theoretically possible. PCBs were commercially 
produced during the 1930s-1970s and were used as dielectric and heat transfer 
fluids in electric transformers and capacitors, wax extenders, organic diluents, 
plasticizers, adhesives, flame retardants and as a source of chlorine content (1, 
2). At least 1.3 million tons of PCBs, comprising about 130 identified individual 
congeners, were manufactured worldwide prior to their banning (3). PCB 
production was prohibited by the United States Congress in 1979 under the Toxic 
Substances Control Act and PCB production was banned internationally at the 
Stockholm Convention on Persistent Organic Pollutants in 2001 (4).  
Although PCB production has been banned for over 30 years, their high 
thermodynamic stability make them resistant to chemical and enzymatic 
degradation in the environment (5) and hence, PCBs, belong to the category of 
“persistent organic pollutants” (POPs). Moreover, PCBs persist in our ecosystem 
globally due to PCB seepage into the environment, accidental spills and improper 
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disposal and are found in soil, atmospheric air, lakes, rivers, aquatic wildlife and 
mammals (6-10). In humans, PCBs, primarily the highly chlorinated congeners 
that are resistant to metabolism, bio-accumulate and are detected in the adipose 
tissue, liver, serum and breast milk (11, 12). 
Currently, PCB exposure in humans is thought to occur primarily through 
ingestion of PCB-contaminated food (13, 14) and to a lesser extent, through 
inhalation of PCB-contaminated air (15, 16). In fact, PCBs continue to be present 
in the food supply and the intake in the American diet is estimated to be 
approximately 30 ng/day based on a study from a Dallas supermarket (17). 
Furthermore, PCBs are the 5th most hazardous substances on the Agency for 
Toxic Substances and Disease Registry (ATSDR) 2013 substance priority list. 
The National Health and Nutrition Examination Study (NHANES) indicated that 
100% of adult NHANES participants had detectable circulating PCB levels and 
PCB 153 (2,2',4,4',5,5'-hexachlorobiphenyl) had the highest median serum 
concentration in humans amongst all PCB congeners (18). Therefore, although 
PCB production has stopped, these compounds are ubiquitous in the 
environment and their resistance to degradation increases the risk of exposure in 
humans.  
PCBs’structure-activity and toxicity relationship  
The PCB’s structure more or less determines the compound’s activity and 
toxicity. PCBs can be classified as either “planar” or “non-coplanar” depending on 
the number and nature of the chlorine substituents in the two phenyl rings, (Fig. 
1.1). Planar PCBs have chlorine substitutions in either the meta- or para- 
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positions but zero or one substituent in the ortho- positions (19). Non-coplanar 
PCBs have ortho- substituted chlorine atoms, apart from meta- and/or para- 
substitutions (19).  
From a mechanistic standpoint, a PCB’s structure determines its ability to 
interact with various receptors (20). PCB studies have demonstrated that planar 
PCBs such as PCB 77 and PCB 126 interact with the aryl hydrocarbon receptor 
(AhR) similar to the classic AhR ligand, 2, 3, 7, 8-tetrachlorodibenzo-p-dioxin 
(TCDD) and hence are also known as “dioxin-like” PCBs (21, 22). On the other 
hand, some non-coplanar PCBs such as PCB 153 and PCB 196 are referred to 
as “phenobarbital-like” PCBs suggesting their activation of the constitutive 
androstane receptor (CAR) (22-24). Moreover, a theoretical structure-activity 
relationship study predicted that non-coplanar PCBs can interact with the 
pregnane xenobiotic receptor (PXR), estrogen receptor, androgen receptor, and 
thyroid receptor as well (25).  
Historically, PCB studies have focused on hepatocarcinogenesis and 
other cancer-related endpoints and attributed the mechanism of toxicity to AhR 
activation (26, 27). However, by mass, dioxin-like PCBs are a relatively minor 
component of the total PCB burden in human serum (18). Moreover, PCBs do 
not appear to be as carcinogenic in man as they are in rodents (eg: PCB 126), 
and this may be due to differences in the AhR structure and in the battery of 
target genes between species (28). In contrast to PCB 126, PCB 153 is an ortho-
substituted, non-coplanar PCB. PCB 153 has been studied extensively by the 
National Toxicology Program (NTP) in female Harlan Sprague-Dawley (SD) rats, 
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and the mode of action has been attributed to the compound’s interaction with 
CAR (23). The studies also demonstrated PCB-induced hepatotoxicity.  
Apart from the structure, a PCB congener’s molecular weight which 
corresponds to the degree of chlorination also dictates the type of toxicity. PCB’s 
metabolism is defined by the number of chlorine atoms present. Low molecular 
weight PCBs (mono-, di-, tri- or tetra-chlorinated) are hydroxylated by 
cytochrome P450 enzymes (29). The metabolized PCBs, also known as bio- 
transformed congeners, can form DNA adducts or bind to proteins to exert their 
toxic effects. High molecular weight PCBs, on the other hand, are resistant to 
metabolism, hence they are known as persistent congeners. Some of these 
PCBs’ half-life is >15 years (30). These lipid-soluble PCBs, including the penta-
chlorinated PCB 126 and hexa-chlorinated PCB 153, bio-accumulate primarily in 
the adipose tissue and have the ability to interact with receptors (1). 
Therefore, depending on the molecular weight of the congener and the 
molecular structure, PCBs have a tendency to induce carcinogenesis by forming 
adducts and through AhR activation. PCB exposure can also cause other 
complications, such as endocrine disruption through other PCB-receptor 
interactions. Additionally, apart from PCB-receptor interactions, nutrient-toxicant 
interactions have also been reported to play a role in health disorders such as 
diet-induced obesity/metabolic syndrome (31) and non-alcoholic fatty liver 















The PCB mixture, Aroclor 1260 
PCBs were commercially marketed and used as mixtures rather than 
individual congeners. Monsanto, a well-known PCB manufacturer in North 
America, produced PCB mixtures under the brand name “Aroclor” at its 
manufacturing plant located in Anniston, Alabama. Incidences of high-level 
environmental contamination during PCB production resulted in increased PCB 
body burden in the Anniston residents (33, 34). PCB production was global with 
PCB mixtures being manufactured worldwide under different brand names 
including Clophens (Germany), Phenoclors and Pyralenes (France), Fenclors 
(Italy), Fenochlors (Spain), Kanechlors (Japan) and Sovol (former USSR) (2).  
Aroclor 1260, a commercial PCB mixture, contained 60% chlorine by 
weight. It was one of the first generation PCB mixtures produced by Monsanto 
during the early stages of PCB production. Aroclor 1260 was later replaced by 
other Aroclors such as Aroclor 1254, Aroclor 1248 and Aroclor 1242 that had 
lower chlorine content by weight (2). Aroclor 1260 is heavily chlorinated and 
contains a limited amount of coplanar congeners (∼1%) (19). It has 
predominantly non-coplanar and di-ortho substituted PCBs that have either 5, 6, 
7, or 8 chlorines (Table 1). As PCBs with low molecular weight are often 
metabolized and eliminated, PCBs that bio-accumulate in humans are typically 
the highly chlorinated congeners with penta-, hexa-, hepta-, and octa 
substituents (35, 36). Thus, for our PCB studies, we selected the PCB mixture 
Aroclor 1260 because its composition best mimics the PCB bioaccumulation 
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profile found in human adipose tissue, rather than reflecting the actual production 





















No. of chlorine Ortho substitution % 
180 7 (Non-coplanar, di-ortho) 11.38 
153 6 (Non-coplanar, di-ortho) 9.39 
149 6 (Non-coplanar, tri-ortho) 8.75 
138 6 (Non-coplanar, di-ortho) 6.54 
187 7 (Non-coplanar, tri-ortho) 5.40 
174 7 (Non-coplanar, tri-ortho) 4.96 
170 7 (Non-coplanar, di-ortho) 4.11 
101 5 (Non-coplanar, di-ortho) 3.13 
151 6 (Non-coplanar, tri-ortho) 3.04 
132 6 (Non-coplanar, tri-ortho) 2.90 
141 6 (Non-coplanar, di-ortho) 2.62 
177 7 (Non-coplanar, tri-ortho) 2.57 
95 5 (Non-coplanar, tri-ortho) 2.45 
163 6 (Non-coplanar, di-ortho) 2.42 
183 7 (Non-coplanar, tri-ortho) 2.41 
194 8 (Non-coplanar, di-ortho) 2.07 
179 7 (Non-coplanar, tetra-ortho) 2.03 
136 6 (Non-coplanar, tetra-ortho) 1.46 
203 8 (Non-coplanar, tri-ortho) 1.40 
110 5 (Non-coplanar, di-ortho) 1.33 
146 6 (Non-coplanar, di-ortho) 1.15 
171 7 (Non-coplanar, tri-ortho) 1.11 
196 8 (Non-coplanar, tri-ortho) 1.09 
135 6 (Non-coplanar, tri-ortho) 1.08 
 
 
Table 1. PCB congener composition in Aroclor 1260. 
Selected PCB congeners present in Aroclor 1260 (≥1% of total composition). 






Figure 1.2. Congener composition in human fat, Aroclor 1260 and 
manufactured PCBs. 
Pie charts depicting the relative abundance of PCB congeners in human 






Effects of PCB exposure in humans 
Historically, PCB toxicity has been linked to cancer, endocrine disruption 
and impaired cognitive development (37-40), but recent epidemiologic studies 
have shown that chronic exposure to these environmental pollutants can result in 
metabolic disorders associated with fatty liver disease, including obesity, insulin 
resistance/diabetes and the metabolic syndrome (18, 34, 41-44). Moreover, other 
complications associated with metabolic disorders such as hypertension and 
cardiovascular disorders have also been associated with PCB exposure (45, 46). 
Furthermore, a follow-up of subjects in the “Yu-cheng” incident in Taiwan 
demonstrated that the mortality rate due to cirrhosis was 2.7-fold higher than 
expected, although pathologic confirmation was not provided (47). The “Yu-
cheng” incident was one of the two known major human PCB intoxication 
episodes, where the victims ingested cooking oil that was highly contaminated 
with PCBs. Additionally; rodent studies have correlated PCB exposures with 
NAFLD, obesity and the metabolic syndrome (48, 49). 
 Our laboratory group recently identified advanced steatohepatitis 
associated with insulin resistance and increased pro-inflammatory cytokines in 
non-obese chemical workers who were subjected to high-level industrial 
chemical exposures (50). The term “toxicant-associated steatohepatitis” (TASH) 
was then coined to describe this condition (51). Our initial work focused on TASH 
in non-obese vinyl chloride workers; in our recent work however, our laboratory 
group identified suspected NAFLD and TASH in the NHANES participants with 
low-level environmental exposures to POPs, including 20 PCBs (18). 
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Epidemiologic studies have reported a positive association between adipose 
tissue concentrations of PCBs and type 2 diabetes (52). High serum PCB levels 
were also associated with elevated serum triglycerides and cholesterol which are 
major risk factors for cardiovascular diseases. Exposure to PCB mixtures has 
also been associated with elevated liver enzymes in plasma and hepatomegaly 
(18, 53). Clearly, environmental exposure to POPs such as PCBs is a major 
health concern, with emerging studies reporting positive associations between 
PCB body burden and suspected liver disease. However, studies involving the 
non-carcinogenic effects of PCB exposure on the liver are scarce and therefore, 
more research is required to evaluate the role of PCB exposure in liver disease, 
particularly NAFLD. 
Non-alcoholic fatty liver disease and xenobiotic receptors 
NAFLD represents a pathological spectrum of diseases ranging from lipid 
accumulation in the hepatocytes (steatosis) to the development of superimposed 
inflammation, leading to non-alcoholic steatohepatitis (NASH) and ultimately 
fibrosis and cirrhosis. NAFLD resembles alcoholic fatty liver disease, although it 
occurs in subjects who do not consume excessive amounts of alcohol. The 
pathogenesis of NAFLD has been reviewed, and key mechanisms included 
altered adipo-cytokines with low adiponectin and high leptin levels (32, 54) and 
elevation of pro-inflammatory cytokines such as TNFα and IL-6 (55). NAFLD 
gives rise to hepatic insulin resistance and systemic inflammation, which in turn, 
exacerbates obesity, diabetes and the metabolic syndrome (56). Because it is 
often seen with insulin resistance and dyslipidemia, NAFLD is generally regarded 
12 
 
to be the hepatic manifestation of obesity and the metabolic syndrome. However, 
NAFLD is also exacerbated by diabetes and is associated with obesity (57), 
indicating a vicious cycle between NAFLD, diabetes/insulin resistance and 
obesity.  
NAFLD and NASH were traditionally associated with the inappropriate 
over- or under-activation of nuclear receptors involved in endobiotic metabolism. 
These receptors include the liver-X-receptor (LXR), farnesoid-X-receptor (FXR) 
and peroxisome proliferator-activated receptors (PPARs) which regulate 
cholesterol, bile acid and lipid metabolism respectively (58, 59). Recent studies 
have implicated the role of hepatic receptors involved in xenobiotic detoxification, 
including PXR, CAR and AhR in NAFLD/NASH. Although these receptors were 
initially thought to be involved only with detoxification and xenobiotic metabolism, 
over-activation or antagonism of these receptors may lead to metabolic diseased 
states such as steatosis and obesity (60-62). Notably, PCBs have been 
demonstrated to interact with AhR, CAR and PXR (22-24, 26, 27). Therefore, it is 
pertinent to study the activation of these xenobiotic receptors by PCBs and their 
contribution to NAFLD with PCB exposure. 
The AhR is a member of the Per Arnt Sim (PAS) domain protein family of 
transcription factors and regulates a battery of genes involved in xenobiotic 
detoxification including CYP1A and CYP1B which can, in turn, bio-transform or 
activate pro-carcinogens to their carcinogenic forms (63, 64). Apart from 
xenobiotic detoxification, the AhR also plays a role in the differentiation of 
developmental pathways such as hematopoiesis (65) and in regulating 
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immunological responses (66). Furthermore, previous work also implicated 
dioxins and dioxin-like PCBs in animal models of steatohepatitis (67, 68).  
On the other hand, PXR, also known as the steroid and xenobiotic sensing 
nuclear receptor (nuclear receptor subfamily 1, group I, member 2, NR1I2) and 
CAR (nuclear receptor subfamily 1, group I, member 3, NR1I2NR1I3) belong to 
the class of nuclear receptors; upon activation by ligands, PXR and CAR 
transcriptionally activate numerous target genes that encode enzymes and 
transporters involved in drug and xenobiotic metabolism (69). However, recent 
studies have demonstrated these receptors’ role in energy homeostasis and 
these include regulation of lipid and carbohydrate metabolism (60, 70). CAR was 
recently named as an anti-obesity nuclear receptor, since its activation improves 
insulin sensitivity in a diet-induced obesity mouse model and ameliorates 
diabetes and fatty liver disease in leptin-deficient mice (71, 72). Activating CAR 
and PXR also induced the anti-lipogenic protein, Insig (73). Furthermore, PXR 
and CAR activation also suppressed gluconeogenesis by decreasing 
gluconeogenic gene expression including phosphoenol-pyruvate carboxykinase 
and glucose-6-phosphatase (74). The reported role of PXR in obesity is 
controversial with some studies demonstrating obesity-protecting effects of PXR 
activation (75) and others illustrating that ablating PXR alleviated diet-induced 
obesity (76, 77). CAR and PXR exert these effects through interactions with other 
transcription factors and receptors including direct protein sequestration. 
Activated nuclear receptors bind to the respective DNA-response elements in the 
promoter regions of the target genes using their conserved DNA-binding domains 
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and promote gene expression (78). These response elements are made up of 
hexameric sequences that can be arranged in different configurations to give 
direct repeats (DR) or inverted repeats. CAR and PXR can bind to similar DNA-
response elements in the promoter region, increasing the probability of crosstalk. 
Therefore, CAR and PXR activation can result in crosstalk with other receptors 
and possibly activation of genes that are not necessarily CAR or PXR targets. 
Significance of studying liver disease 
NAFLD affects up to 46% of the US population and approximately 20% of 
the population worldwide and it is the most prevalent liver disease in North 
America (79-81). It is more common in men than women until the age of 60 when 
the prevalence matches and the lower rate of NAFLD in women is attributed to 
the protective nature of estrogen in fatty liver disease. The prevalence of NAFLD 
is still growing and it is higher in the Hispanic population, which can be attributed 
to high rates of obesity and type 2 diabetes in this population (82).  NAFLD is not 
an independent entity by itself but it is closely related to obesity, insulin 
resistance and the metabolic syndrome. The association between NAFLD and 
obesity poses a great concern to human health because obesity has been 
identified as a leading “preventable cause of death” by the World Health 
Organization (WHO), and many health authorities view it as one of the most 
serious health problems of the 21st century. The annual cost of obesity treatment 
in the US alone was recently estimated at $147 billion (83) . According to the 
data from NHANES 2007-2008, 33.8% of US adults are obese (defined by body 
mass index, BMI ≥ 30) with another 34.2% being overweight (defined by BMI ≥ 
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25). Alarmingly, obesity is not restricted to the adult population; 15% of children 
and adolescents in the US are obese (84). Overweight/obesity is one of the 
defining features of the metabolic syndrome, a metabolic disorder which is also 
characterized by insulin resistance, hypertension, and dyslipidemia. The 
prevalence of metabolic syndrome in US adults was recently estimated at 34.3%. 
The obesity epidemic is strongly associated with increased type 2 diabetes which 
is the late stage of insulin resistance. The National Diabetes Fact Sheet obtained 
from the Center for Disease Control and Prevention (CDC, 2011) reports that 
25.8 million Americans have diabetes with another 79 million being insulin 
resistant. Obesity, insulin resistance, and metabolic syndrome can eventually 
lead to target organ damage contributing to  cardiovascular disease, chronic 
kidney disease, and cancer (85-87). Therefore, taking the above mentioned 
statistics into consideration, studying the causal factors of NAFLD is relevant to 
public health. 
Overall goal and specific aims 
The pathogenesis of NAFLD, obesity, insulin resistance, and the 
metabolic syndrome is complex. NAFLD and obesity were linked to high caloric 
intake and over-nutrition, physical inactivity, genetic background, and certain 
medications’ side effects. Interestingly, inflamed and fatty liver conditions are not 
confined to obese individuals only, but other factors can predispose a person to 
steatohepatitis. It is possible that primary factors such as consumption of hyper-
caloric foods can lead to steatosis in normal individuals, thus acting as a ‘first hit’. 
Emerging studies have demonstrated that other factors may play a role in the 
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genesis and development of NAFLD or may act as a ‘second hit’ in the 
progression of hepatic steatosis to steatohepatitis (88). These factors may 
include exposure to environmental contaminants including PCBs, 
bromodichloromethane (BDCM) and organochlorine pesticides, such as, dieldrin 
and dichlorodiphenyltrichloroethane (DDT) (41, 89). Our laboratory group 
recently identified industrial chemicals and environmental pollutants that are 
associated with toxicant-associated fatty liver disease and toxicant-associated 
steatohepatitis (TASH) using two federal databases (90). Such compounds have 
the capacity to act as key players in the development of NASH, obesity and the 
metabolic syndrome but the number of studies on the effects of environmental 
pollutants in liver disease is still modest and needs to be investigated. 
The overall goal of this dissertation is to evaluate the role of PCB 
exposure in fatty liver disease and elucidate the potential PCB-receptor 
interactions that mediate fatty liver disease. The outcomes from this study would 
benefit our understanding of TASH and the underlying mechanisms caused by 
toxicant exposure in TASH. The specific aims of the project are as follows: 
1A. Develop a mouse model for PCB exposure that simulates human 
exposure paradigms.  
1B. Evaluate the effects of the commercialized PCB mixture, Aroclor 
1260, in obesity and NAFLD. 
The congener composition in the PCB mixture, Aroclor 1260, resembles 
bio-accumulated PCBs present in human adipose tissue (Fig. 1.2) and it was 
therefore chosen for this study. Prior to initiating the animal experiments 
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described in this dissertation, there were no documented studies on animal 
models using PCB mixtures that simulate bio-accumulated PCBs and at doses 
relevant to human exposure. Additionally, the effects of Aroclor 1260 in diet-
induced steatosis and obesity have never been assessed.  The purpose of the 
studies in Chapter 2 was to develop a mouse model to study the effects of PCB 
exposure at doses relevant to human exposure. Additionally, the experiments in 
Chapter 2 were designed to determine if Aroclor 1260 exposure by itself could 
induce NAFLD or if it worsens NAFLD and obesity caused by high fat diet 
feeding. 
2. Determine the role of the nuclear receptors, CAR and PXR, in liver 
injury caused by Aroclor 1260 and high fat diet co-exposure. 
CAR and PXR are involved in drug metabolism but recent studies have 
demonstrated in the role of these receptors in maintaining energy homeostasis in 
the body (60-62). Moreover, theoretical structure activity relationship studies 
predicted that non-coplanar PCBs can interact with CAR and PXR (25).  
However activation of CAR and PXR by a PCB mixture and the subsequent 
contribution of these activated receptors to PCB effects and toxicity have not 
been thoroughly evaluated, especially in terms of obesity and NAFLD/NASH. The 
experiments described in Chapter 3 examined the role of CAR and PXR in the 
context of liver injury caused by Aroclor 1260 exposure and high fat diet feeding. 
3. Examine the interactions between Aroclor 1260/selected PCB 
congeners and human receptors in the liver 
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We hypothesized that PCBs may exert some of their toxic effects, such as 
NAFLD, by interacting directly with the endobiotic nuclear receptors (LXR, FXR, 
PPARs) or with xenobiotic receptors (AhR, CAR and PXR). Moreover, the 
interaction between Aroclor 1260 and these receptors that are implicated in 
NAFLD have never been tested. The purpose of the studies in Chapter 4 is to 
evaluate human receptor agonism/antagonism by the PCB mixture, Aroclor 1260, 
and selected PCB congeners that are highly represented in this mixture. We 
determined human receptor activation by utilizing transient transfection assays in 
human hepatoma-derived (HepG2) and primate-derived (COS-1) cell lines. 















EVALUATING THE EFFECTS OF AROCLOR 1260 IN A DIET-INDUCED 
OBESITY MOUSE MODEL 
INTRODUCTION 
 As aforementioned, previous studies on PCBs were focused on 
carcinogenicity and acute toxicity; however, the effects of chronic low-level 
exposures to PCBs on other pathologies such as NAFLD, diabetes and obesity 
are understudied, especially for PCB mixtures. Epidemiological studies have 
found associations between PCB exposures and metabolic disorders related to 
NAFLD, including obesity, diabetes/insulin resistance and the metabolic 
syndrome. In our recent work, we demonstrated that PCB 153 administration was 
a relevant ‘second hit’ mechanism that worsened NAFLD/obesity occurring in the 
context of a high fat diet (HFD) in male C57Bl/6 mice (48). However, no 
individual is exposed to a single PCB congener alone and therefore studying a 
PCB mixture may better simulate human PCB exposure patterns. Moreover, the 
composition of PCB congeners in Aroclor 1260 mimics human bioaccumulation 
patterns (36).  
The primary toxicity endpoint of PCB exposure has been an increase in 
cancer and is thought to be mediated through PCB interaction with transcription 
factors namely the AhR. Genotoxic carcinogenic mechanisms are activated via 
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induction of the AhR and the carcinogenicity of a PCB mixture is often defined as 
its ability to induce the AhR-dependent gene transcription relative to the potent 
rodent carcinogen and prototypical AhR ligand, TCDD. In addition, “non 
genotoxic” carcinogenic mechanisms may also be induced including 
hepatomegaly by the nuclear receptors, CAR and PXR. Although these receptors 
are primarily involved in xenobiotic detoxification, recent studies have implicated 
their role in metabolic diseased states such as steatosis, obesity and insulin 
resistance (60-62). The role of hepatic receptor-PCB interactions in NASH and 
the metabolic syndrome is understudied and requires further investigation.  
It is therefore pertinent to evaluate the effects of a commercially produced 
PCB mixture whose composition is relevant to human PCB body burden, in a 
normal and hyper- caloric state, and investigate nutrient-toxicant interactions that 
can contribute to liver disease and obesity. We hypothesize that the commercial 
PCB mixture, Aroclor 1260, like PCB 153, can act as an obesogen and 
promote/worsen steatosis and diet-induced obesity. In this study, we utilized a 
mouse model to determine if i) Aroclor 1260 exposures alone are sufficient to 
cause NAFLD and obesity; ii) Aroclor 1260 worsens diet-induced obesity and 
NAFLD by exacerbating insulin resistance, adipocytokine dysregulation, 
alterations in hepatic gene expression, AhR, PXR and CAR activation and other 
implicated mechanisms; and iii) effects observed with Aroclor 1260 
administration are dependent on PCB dose.  
The results of the current study established Aroclor 1260 as a “second hit” 
driving steatosis to steatohepatitis in HFD-fed mice. The results also 
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demonstrated that selective hepatic receptor activation by this PCB mixture was 
dependent on exposure dose and diet, in part, clarifying the mechanism of action 




















MATERIALS AND METHODS 
Animals and diets 
The animal protocol was approved by the University of Louisville 
Institutional Animal Care and Use Committee. Male C57Bl/6J mice (8 weeks old; 
The Jackson Laboratory, Bar Harbor, ME, USA) were divided into 6 study groups 
(n=10) based on diet and Aroclor 1260 exposure in this 12 week study utilizing a 
2x3 design. Mice were fed either a control diet (CD, 10.2% kCal from fat; 
TD.06416 Harlan Teklad) or a HFD (42% kCal from fat; TD.88137 Harlan 
Teklad). Diet components are described in Table 2. Aroclor 1260 (AccuStandard, 
CT, USA) was administered in corn oil by oral gavage (vs. corn oil alone) at two 
doses; a low dose of 20 mg/kg which was designed to mimic the maximum 
human PCB exposures seen in the Anniston cohort and a high dose of 200 
mg/kg which was similar to that used in rodent carcinogenesis studies (18, 22). 
The 20 mg/kg dose was administered on Week 1 whereas the 200 mg/kg dose 
was administered as four individual doses of 50 mg/kg each on Weeks 1, 3, 5, 
and 7 to ensure that acute toxicity was minimized (Fig. 2.1). Mice were housed in 
a temperature- and light controlled-room (12 hour light; 12 hour dark) with food 
and water ad libitum. A glucose tolerance test was performed at Week 11, and 
the animals were euthanized (ketamine/ xylazine, 100/20 mg/kg body weight, 
i.p.) at the end of Week 12. Prior to euthanasia, the animals were analyzed for 
body fat composition by dual energy X-ray absorptiometry (DEXA) scanning 
(Lunar PIXImus densitometer, WI, USA). Thus six different treatment groups 
were evaluated in this fashion: CD+vehicle, CD+Aroclor 1260 (20 mg/kg), 
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CD+Aroclor 1260 (200 mg/kg), HFD+vehicle, HFD+Aroclor 1260 (20 mg/kg), 
























    Control Diet   High Fat Diet 
%kCal Source %kCal Source 







Fat 10.2 Lard 42 
Anhydrous 
Milkfat 
kCal/g 3.7 4.5 
 




























Glucose tolerance test 
On the day of the test, mice were fasted for 6 h (7a.m.-1 p.m.), and fasting 
blood glucose levels were measured with a hand-held glucometer (ACCU-
CHECK Aviva, Roche, Basel, Switzerland) using 1-2 µL blood via tail snip. 
Glucose was then administered (1 mg glucose/g body weight, sterile saline, i.p.), 
and blood glucose was measured at 5, 15, 30, 60, 90 and 120 min post injection. 
Insulin resistance was calculated by homeostasis model assessment using the 
formula: homeostasis model assessment of insulin resistance (HOMA-
IR)=Fasting glucose (mg/dL) x Fasting insulin (µU/mL)/405.   
Histological studies 
Liver and adipose sections were fixed in 10% neutral buffered formalin 
and embedded in paraffin for routine histological examination. Tissue sections 
were stained with hematoxylin-eosin (H&E) or for chloroacetate esterase activity 
[CAE, Naphthol AS-D Chloroacetate (Specific Esterase) Kit, Sigma Aldrich, St. 
Louis, MO, USA] and examined by light microscopy. Photomicrographic images 
were captured using a high-resolution digital scanner at 10x and 40x 
magnification. After H&E staining, adipocyte size was measured using Image J 
software version 1.47 (NIH, Bethesda, MD, USA). 
Cytokine and adipokine measurement 
 Plasma cytokine and adipokine levels were measured using the Milliplex 
Serum Cytokine and Adipokine Kits (Millipore Corp, Billerica, MA, USA) on the 
Luminex IS 100 system (Luminex Corp, Austin, TX, USA), as per the 
manufacturer’s instructions. Plasma aspartate transaminase (AST) activity, 
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alanine transaminase (ALT) activity, low density lipoprotein (LDL), high density 
lipoprotein (HDL), triglycerides and cholesterol levels were measured with the 
Piccolo Xpress Chemistry Analyzer using Lipid Panel Plus reagent discs (Abaxis, 
Union City, CA, USA). 
Measurement of hepatic triglyceride and cholesterol content 
Mouse livers were washed in neutral 1X phosphate buffered saline and 
pulverized. Hepatic lipids were extracted by an aqueous solution of chloroform 
and methanol, according to the Bligh and Dyer method (91), dried using nitrogen, 
and resuspended in 5% lipid-free bovine serum albumin. Triglycerides and 
cholesterol were quantified using the Cobas Mira Plus automated chemical 
analyzer. The reagents employed for the assay were L-Type Triglyceride M 
(Wako Diagnostics, Richmond, VA, USA) and Infinity Cholesterol Liquid Stable 
Reagent (Fisher Diagnostics, Middletown, VA, USA) for triglycerides and 
cholesterol respectively. 
Real-time PCR 
Animal liver and adipose tissue samples were homogenized and total 
RNA was extracted using the RNA-STAT 60 protocol (Tel-Test, Austin, TX, 
USA). RNA purity and quantity were assessed with the Nanodrop (ND-1000, 
Thermo Scientific, Wilmington, DE, USA) using the ND-1000 V3.8.1 software. 
cDNA was synthesized from total RNA using the QuantiTect Reverse 
Transcription Kit (Qiagen, Valencia, CA, USA). Polymerase Chain Reaction 
(PCR) was performed on the Applied Biosystems StepOnePlus Real-Time PCR 
Systems using the Taqman Universal PCR Master Mix (Life Technologies, 
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Carlsbad, CA, USA). Primer sequences for Taqman Gene Expression Assays 
(Applied Biosystems, Foster City, CA) were as follows: tumor necrosis factor 
alpha (TNFα); (Mm00443258-m1), fatty acid synthase (FAS); (Mm00662319-
m1), peroxisome proliferator-activated receptor alpha (PPARα); (Mm00440939-
m1), carnitine palmitoyl transferase 1A (CPT1A); (Mm01231183-m1), sterol 
regulatory element binding protein (SREBP-1c); (Mm00550338-m1), cytochrome 
P450s [Cyp4a10 (Mm02601690-gH), Cyp2b10 (Mm01972453-s1), Cyp3a11 
(Mm007731567-m1), Cyp1a2 (Mm00487224-m1)], CD36 (Mm01135198-m1), 
phosphoenolpyruvate carboxy kinase (PEPCK-1); (Mm01247058-m1), stearoyl 
coenzyme A desaturase1 (SCD1); (Mm00772290-m1), interleukin 6 (IL-6); 
(Mm00446190-m1), monocyte inducible protein 1 (MIP1); (Mm00441258-m1), 
monocyte chemo attractant protein 2 (MCP2); (Mm01297183-m1),  transforming 
growth factor-beta (TGFβ); (Mm01178820_m1), collagen 1α1 
(Mm00801666_g1), tissue inhibitor of metalloproteinases-1 (TIMP-1); 
(Mm00441818_m1) and glyceraldehyde-3-phosphate dehydrogenase (GAPDH); 
(4352932E). The levels of mRNA were normalized relative to the amount of 
GAPDH mRNA, and expression levels in mice fed control diet and administered 
vehicle were set at 1. Gene expression levels were calculated according to the 
2−∆∆Ct method (92). 
Statistical Analysis 
Statistical analyses were performed using GraphPad Prism version 5.01 
for Windows (GraphPad Software Inc., La Jolla, CA, USA). Data are expressed 
as mean ± SEM. Multiple group data were compared using One Way ANOVA 
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followed by Bonferroni's post-hoc test (for parametric data) or Kruskal-Wallis test 
followed by Dunn’s Multiple Comparison Test (for nonparametric data). P <0.05 



















Aroclor 1260 decreased body weight and visceral adiposity in mice fed 
high fat diet, but had no effect in mice fed control diet 
During the 12-week study, body weight gain was measured and percent 
(%) increase in bodyweight was calculated (Fig. 2.2 A&B). All the HFD groups 
experienced weight gain vs. CD groups. Aroclor 1260 administration did not 
further increase the body weight of mice consuming HFD. Rather, Aroclor 1260 
at 200 mg/kg decreased the body weight gain in HFD-fed mice vs. HFD+vehicle 
group (171.7±8.9% vs. 156.9±11.3%, p <0.05). Aroclor 1260 at 20 mg/kg had no 
effect on body weight in HFD or CD groups. The % body fat composition was 
evaluated by DEXA scanning prior to harvesting the animals (Fig. 2.2 C). HFD 
consumption increased total body fat. Aroclor 1260 at both doses diminished the 
increase in % body fat composition in HFD-fed mice (p <0.05) but not in CD-fed 
mice. In fact, mice co-exposed to HFD and Aroclor 1260 (20 mg/kg) appeared to 
have an increase in lean body mass as compared to HFD-fed mice only (Fig. 2.2 
D). There were no differences in % fat composition in CD-fed mice exposed to 
Aroclor 1260 vs. CD+vehicle group. The pattern of epididymal fat to body weight 
ratio among the six groups was similar to the pattern of body fat composition 
obtained by DEXA scanning, further supporting the observation that Aroclor 1260 
exposure attenuated the increase in % body fat caused by HFD feeding (Fig. 2.2 
E).  
Mean epididymal adipocyte area (µm2) was larger in HFD+vehicle vs. 
CD+vehicle (p <0.05). However, Aroclor 1260 had no effect at any of the doses 
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administered, either in mice fed CD or HFD (Fig. 2.2 F&G). Food consumption 
per mouse per day (g) was calculated over the 12-week period of study. Although 
all the HFD groups of animals consumed more food (approximately 1.7-fold more 
calories) as compared to CD groups, Aroclor 1260 did not alter the food 
consumption rate (Fig. 2.2 H). Thus, Aroclor 1260 exposure at both doses did not 























Figure 2.2. Effects of Aroclor 1260 exposure on body weight and visceral 
adiposity.  
(A) Increase in body weight with time for C57BL/6 mice (n=10) fed with a 
42% milk fat diet (vs. CD). Body weight measurements were taken from Week 1 
to Week 12 (12 weeks). (B) The % increase in body weight gain with time was 
calculated and the body weight at Week 1 was taken as 100%. (C) The % fat 
composition was measured using the Lunar PIXImus densitometer (DEXA 
scanner). Aroclor 1260 (20 and 200 mg/kg) exposure lowered % fat composition 
in HFD-fed mice vs. HFD+vehicle group. (D) The lean tissue mass (g) was also 
measured using the DEXA scanner. (E) Epididymal weight (EW) to body weight 
(BW) ratio was calculated for all groups of mice. (F & G) Epididymal adipose 
tissue was stained with H&E. and the adipocyte size (µm2) was measured. The 
average cell size of >100 cells for each group was calculated. (H) Food 
consumption throughout the 12-week study was measured. Values are mean ± 
SEM, p <0.05, a- ∆ due to HFD. CD-control diet, HFD-high fat diet, Ar-Aroclor 









 Aroclor 1260 exposure caused increased liver injury in HFD-fed mice  
CD-fed mice with or without Aroclor 1260 exposure did not develop 
steatosis or steatohepatitis as seen with H&E staining of the liver sections (Fig. 
2.3 A). Mice fed with HFD developed steatosis in both the unexposed and 
Aroclor 1260-exposed groups. The most striking difference between the HFD and 
HFD+Aroclor 1260 groups was transformation from steatosis to steatohepatitis. 
HFD+Aroclor 1260 co-exposures resulted in scattered foci of mononuclear cells 
and neutrophils (confirmed with CAE stained slides) and hepatocyte necrosis 
which appeared greater in the high dose group (Fig. 2.3 A&B). Aroclor 1260 
exposure was associated with centrilobular enlargement of hepatocytes and 
karyomegaly irrespective of diet type, possibly reflecting hepatic enzyme 
induction in these mice. Liver to body weight ratio was calculated and there were 
no differences among the groups (Fig. 2.3 C). No inflammation was observed in 
Aroclor 1260-exposed mice fed CD. 
Liver injury, as determined by elevated serum ALT levels, was most 
noticeable in the HFD+Aroclor 1260 (20 mg/kg) group (p <0.05) while serum AST 
was unaffected (Fig.  2.3 D&E). Although the higher exposure group (200 mg/kg) 
fed HFD tended to have more inflammatory foci based on histological 
assessment, serum ALT levels were not significantly elevated in this group. In 
the CD-fed mice, Aroclor 1260 exposure did not alter the serum ALT and AST 
levels at either dose. Hepatic expression of fibrotic markers including 
transforming growth factor-beta (TGFβ), collagen 1α1 and tissue inhibitor of 
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metalloproteinases-1 (TIMP-1) were measured (Fig. 2.3 F,G&H) and there was 
no increase in mRNA levels among the HFD groups. 
The HFD+vehicle group showed a significant increase in hepatic levels of 
cholesterol and triglycerides vs. any of the CD groups (Fig. 2.4 A&B). However, 
hepatic cholesterol and triglycerides levels were not significantly increased in the 
HFD+Aroclor 1260 at 20 or 200 mg/kg vs. any of the CD groups. Likewise, 
hepatic cholesterol and triglycerides levels were not significantly increased in the 
HFD+Aroclor 1260 at 20 or 200 mg/kg vs. the HFD group alone. Rather, there 
was a trend towards decreased hepatic cholesterol and triglycerides with Aroclor 
1260 exposure in HFD-fed mice but this was not significant. Taken together, 
these results suggest that Aroclor 1260 exposure did not worsen steatosis 















Figure 2.3. Aroclor 1260 exposure caused steatohepatitis in HFD-fed mice 
but had no effect on fibrotic markers. 
 (A) H&E staining of hepatic sections established the occurrence of 
centrilobular hepatocellular hypertrophy, karyomegaly, and multinucleate (arrow 
head) hepatocytes in the CD+Aroclor 1260 (200mg/kg) group [A]. HFD 
consumption resulted in variable, centrilobular, microvesicular lipidosis [B-D], 
while centrilobular hepatocellular hypertrophy was observed in HFD+Aroclor 
1260 (20mg/kg) mice [C]. HFD-fed mice exposed to Aroclor 1260 (200mg/kg) 
exhibited occasional, small areas of necrosis and inflammation (steatohepatitis) 
[D], characterized by neutrophils (arrow head) and pyknotic debris (arrow). (B) 
CAE staining demonstrated neutrophil infiltration in the HFD+Aroclor 1260 (20 
and 200 mg/kg) groups. (C) The liver weight (LW) to body weight (BW) ratio was 
calculated. (D) Serum ALT and (E) AST levels (U/L) were measured (n=10) using 
the Piccolo Xpress chemical analyzer. Real-time PCR experiments were 
performed to measure the hepatic expression of (F) TGFβ, (G) Collagen1α1 and 
(H) TIMP-1, n=10. Values are mean ± SEM, p <0.05, a- ∆ due to HFD, b- ∆ due 
to Aroclor 1260 exposure at 20 mg/kg. CD-control diet, HFD-high fat diet, Ar-
Aroclor 1260, PV-portal vein, CV-central vein. Figure adapted from Wahlang et 















Figure 2.4. Effects of Aroclor 1260 exposure on hepatic cholesterol and 
triglycerides. 
Hepatic levels of (A) cholesterol and (B) triglycerides were quantified 
(µg/mg tissue) in mice (n=5) fed with CD or HFD with or without Aroclor 1260 co-
exposure. Values are mean ± SEM, p <0.05, a- ∆ due to HFD. CD-control diet, 
HFD-high fat diet, Ar-Aroclor 1260. Figure adapted from Wahlang et al., Toxicol 

















Effects of Aroclor 1260 exposure on serum adipo-cytokines 
HFD consumption alone did not increase serum interleukin 6 (IL-6) or 
tissue plasminogen activator inhibitor (tPAI-1) levels vs. CD (Fig. 2.5 A&B).  
However, HFD-fed mice exposed to Aroclor 1260 at 20 mg/kg displayed 
significantly elevated serum IL-6 and tPAI-1 levels (p <0.05). This exposure-
related elevation in pro-inflammatory cytokines was absent in CD-fed mice. In 
contrast to the lower exposure, Aroclor 1260 at 200 mg/kg did not increase 
serum IL-6 or tPAI-1 levels in either the HFD or CD groups even though 
histological examinations indicated higher levels of hepatic macrophage 
infiltration in HFD fed animals. Serum tumor necrosis factor alpha (TNFα) and 
monocyte chemo attractant protein-1 (MCP1) levels were not affected by either 
diet or Aroclor 1260 exposure (Fig. 2.5 C&D).  
All the HFD groups displayed elevated serum leptin levels as compared to 
CD groups (Fig. 2.5 E, p <0.05) consistent with the increased adiposity observed 
in these groups. Exposure to Aroclor 1260 did not affect leptin levels. 
Interestingly, serum adiponectin levels did not differ between any of the groups, 
irrespective of the diet type consumed (Fig. 2.5 F), leading to an increased 
leptin/adiponectin ratio in HFD-fed animals. Similar to leptin, serum resistin levels 
were increased in mice fed HFD (Fig. 2.5 G, p <0.05). Furthermore, Aroclor 1260 
at 200 mg/kg decreased serum resistin levels in HFD-fed mice vs. HFD+vehicle 
and HFD+Aroclor 1260 (20 mg/kg) groups (p <0.05), indicating a dose-
dependent interaction between Aroclor 1260 and HFD. In summary, Aroclor 1260 
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at the lower dose increased serum pro-inflammatory cytokines in HFD-fed mice, 
























Figure 2. 5. Effects of Aroclor 1260 on serum adipo-cytokines. 
Serum (A) IL-6 (pg/mL), (B) tPAI-1 (pg/mL), (C) TNFα (pg/mL), (D) MCP1 
(pg/mL), (E) leptin (pg/mL), (F) adiponectin (µg/mL) and (G) resistin (pg/mL) 
levels were measured using the Luminex IS 100 system (n=10). Values are 
mean ± SEM, p <0.05, a- ∆ due to HFD, b- ∆ due to Aroclor 1260 exposure at 20 
mg/kg, c- ∆ due to Aroclor 1260 exposure at 200 mg/kg. CD-control diet, HFD-
high fat diet, Ar-Aroclor 1260. Figure adapted from Wahlang et al., Toxicol Appl 

















Effects of Aroclor 1260 on insulin resistance, glucose regulation, and 
serum lipids 
A glucose tolerance test was performed and HOMA-IR was calculated to 
determine if HFD and Aroclor 1260 co-exposure exacerbate HFD-induced insulin 
resistance, a common hallmark of NAFLD. HFD feeding increased HOMA-IR and 
Aroclor 1260 exposure (200 mg/kg) decreased HOMA-IR in HFD-fed mice (Fig. 
2.6 A). The HFD group showed greater area under the curve (AUC) in the 
glucose tolerance test than any of the CD groups (Fig. 2.6 B&C). Aroclor 1260 
though had no additive effect to dietary manipulation alone. Therefore, while 
Aroclor 1260 exposure (200 mg/kg) decreased HOMA-IR, there was no 
difference in the AUC. The decrease in HOMA-IR could indicate impaired 
glucose-stimulated insulin production with Aroclor 1260 exposure. Fasting blood 
glucose levels showed that Aroclor 1260 exposure lowered blood glucose levels 
in the CD-fed mice at both the 20 and 200 mg/kg doses but not in HFD-fed mice 
(Fig. 2.6 D). This observation is consistent with our earlier study where i.p. 
injection of PCB 153 resulted in lowered fasting blood glucose levels in mice fed 
CD (48).  
HFD feeding resulted in significantly higher mean serum cholesterol and 
HDL levels vs. CD feeding (p <0.05). Aroclor 1260 exposure at 20 or 200 mg/kg 
did not affect mean cholesterol and HDL levels either in the HFD or CD groups 
(Table 3). In contrast, HFD feeding did not increase mean serum LDL levels vs. 
CD feeding. However, the HFD+Aroclor 1260 (200 mg/kg) group exhibited 
significantly higher mean LDL levels vs. CD+vehicle or CD+Aroclor 1260 (200 
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mg/kg). Mean serum triglyceride levels were unchanged irrespective of diet 
consumed or level of Aroclor 1260 exposure. In summary, HFD was associated 
with insulin resistance and serum hypercholesterolemia, but Aroclor 1260 had no 




































Figure 2.6.HFD increased insulin resistance, and this was unaffected by 
Aroclor 1260 co-exposure. 
 (A) HOMA-IR was calculated from fasting blood glucose and insulin levels 
for all six groups of animals (n=10). (B) Glucose tolerance test was performed, 
and blood glucose levels were measured for mice (n=10) fed with CD or HFD, 
with or without Aroclor 1260 co-exposure. AUC was calculated (C), and the HFD 
groups showed higher AUC levels than the CD groups. (D) Fasting blood glucose 
levels (mg/dL) were measured, and the CD-fed mice co-exposed to Aroclor 1260 
showed lower levels vs. CD+vehicle.Values are mean ± SEM, p <0.05, a- ∆ due 
to HFD, b- ∆ due to Aroclor 1260 exposure at 20 mg/kg, c- ∆ due to Aroclor 1260 
exposure at 200 mg/kg. CD-control diet, HFD-high fat diet, Ar-Aroclor 1260. 














Cholesterol HDL LDL Triglycerides
CD 70.1 ± 7.7 49.1 ± 6.1 12.3 ± 1.7 44.1 ± 6.1 
CD+Ar 
(20 mg/kg) 
76.0 ± 3.9 52.2 ± 3.0 16.1 ± 1.3 40.2 ± 3.6 
CD+Ar 
(200 mg/kg) 
76.8 ± 3.8 56.0 ± 3.0 12.0 ± 1.6 43.8 ± 6.3 
HFD 122.1 ± 11.4a 96.8 ± 9.8a 17.3 ± 1.8 38.6 ± 3.1 
HFD+Ar 
(20 mg/kg) 
130.4 ± 8.2a 92.2 ± 4.4a 15.5 ± 2.3 53.0 ± 3.3 
HFD+Ar (200 
mg/kg) 
130.0 ± 5.3a 93.1 ± 2.7a 21.8 ± 1.4c 50.0 ± 3.1 
 
Table 3. Serum levels of cholesterol, high density lipoproteins, low density 
lipoproteins and triglycerides. 
Values are mean ± SEM (mg/dL), p <0.05, a- ∆ due to HFD, b- ∆ due to 
Aroclor 1260 exposure at 20 mg/kg, c- ∆ due to Aroclor 1260 exposure at 200 
mg/kg. CD-control diet, HFD-high fat diet, Ar-Aroclor 1260, HDL-high density 
lipoproteins, LDL-low density lipoproteins. Table adapted from Wahlang et al., 








Aroclor 1260 exposure modulated hepatic fat metabolism 
Liver-X-receptor (LXR) is the key transcription factor that drives lipid 
synthesis and cholesterol metabolism and its over-activation can promote or 
worsen steatosis (93). We were interested in evaluating if Aroclor 1260 exposure 
would increase LXR target gene expression, which in turn, worsens steatosis 
caused by HFD.  There are similarities in the response elements, to which LXR 
and the receptors that PCBs activate (CAR and PXR), bind to. All three receptors 
have the capacity to bind direct repeats (DR-4) response elements suggesting 
that some degree of crosstalk may be possible. HFD feeding did not alter FAS 
hepatic expression vs. CD feeding (Fig. 2.7 A). However, Aroclor 1260 exposure 
at 20 and 200 mg/kg decreased FAS hepatic expression in HFD-fed mice (p 
<0.05). HFD feeding increased SCD1 hepatic expression (Fig. 2.7 B, p <0.05) 
and this result was not affected by Aroclor 1260 exposure. Interestingly, HFD 
feeding alone decreased SREBP-1c mRNA levels but co-exposure to HFD and 
Aroclor 1260 at both doses resulted in increased SREBP1-c mRNA levels (Fig. 
2.7 C, p <0.05), suggesting an interaction between HFD and Aroclor 1260 
exposure. Aroclor 1260 exposure at both doses had no effect on SREBP-1c 
hepatic expression in CD-fed mice. In contrast, Aroclor 1260 exposure at 20 
mg/kg resulted in hepatic upregulation of CD36 in CD-fed mice (Fig. 2.7 D, p 
<0.05). Notably, CD36 is an LXR target gene shared by PXR as well (94). In 
summary, Aroclor 1260 exposure did not increase FAS or SCD1 hepatic 
expression, suggesting that LXR was not activated by the exposure but that 
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these genes’ expression may have been modulated by CAR or PXR directly or 
indirectly. 
PPARα is a transcription factor for lipid-catabolizing genes including 
CPT1A, CPT2 and Cyp4b10. PPARα activation results in hepatic lipid oxidation 
and may be protective against steatosis. We measured the hepatic expression of 
PPARα as well as its target genes, Cyp4b10 and CPT1A (Fig. 2.8 A, B&C). The 
mRNA levels of PPARα and Cyp4b10 did not differ between any of the groups 
examined. However, CPT1A expression was significantly induced with low dose 
Aroclor 1260 exposure in the HFD group vs. HFD alone. Therefore, Aroclor 1260 
exposure at 20 mg/kg appeared to induce CPT1A in a HFD-setting by 
















Figure 2.7. Effects of Aroclor 1260 exposure on genes involved in lipid 
metabolism. 
Real-time PCR experiments showed the changes in hepatic mRNA 
expressions caused by Aroclor 1260 exposure for (A) FAS, (B) SCD1, (C) 
SREBP-1c and (D) CD36. Values are mean ± SEM, p <0.05, a- ∆ due to HFD, b- 
∆ due to Aroclor 1260 exposure at 20 mg/kg, c- ∆ due to Aroclor 1260 exposure 
at 200 mg/kg. CD-control diet, HFD-high fat diet, Ar-Aroclor 1260. Figure adapted 











Figure 2.8. Effects of Aroclor 1260 exposure on genes involved in lipid 
oxidation. 
Real-time PCR experiments showed the changes in hepatic mRNA 
expressions caused by Aroclor 1260 exposure for of (A) Cyp4a10 (B) CPT1A 
and (C) PPARα. Values are mean ± SEM, p <0.05, b- ∆ due to Aroclor 1260 
exposure at 20 mg/kg. CD-control diet, HFD-high fat diet, Ar-Aroclor 1260. Figure 


















Hepatic expression of TLR-4 target genes 
Toll like receptor 4 (TLR-4) activation results in nuclear factor kappa-B 
(NF-κB) activation which in turn causes upregulation of pro-inflammatory 
cytokines (95). We hypothesized that Aroclor 1260 may interact directly or 
indirectly with TLR-4, resulting in monocytic infiltration as observed in liver 
histology and increased serum cytokine levels. We therefore measured the 
hepatic expression of TLR-4 target genes namely TNFα and IL-6. HFD alone did 
not increase TNFα mRNA levels (Fig. 2.9 A). However, exposure to Aroclor 1260 
at 20 mg/kg increased TNFα mRNA levels in HFD-fed mice (p <0.05). Aroclor 
1260 exposure at 200 mg/kg did not increase TNFα hepatic expression in either 
the CD- or HFD-fed mice. Aroclor 1260 exposure at 20 mg/kg in CD fed mice 
resulted in increased IL-6 mRNA levels vs. CD alone (Fig. 2.9 B). Aroclor 1260 
exposure at 200 mg/kg did not increase IL-6 mRNA levels in either the CD- or 
HFD-fed mice. Clearly, Aroclor 1260 exposure at 20 mg/kg led to increased 
TNFα and IL-6 hepatic expressions with either HFD or CD respectively. Neither 
HFD feeding nor Aroclor 1260 exposure had any effect on MCP2 mRNA levels 
whereas MIP1α mRNA levels was increased only with HFD feeding (Fig. 2.9 
C&D). These results appear broadly consistent with the serum cytokine levels 
data, suggesting increased inflammation and possibly sensitization to TNFα-
dependent cell death only at the lower dose of Aroclor 1260 (20mg/kg). 
Furthermore, the results also suggest that cytokine production may be inhibited 

















Figure 2.9. Effects of Aroclor 1260 exposure on TLR-4 target genes. 
Real-time PCR experiments showed the changes in hepatic mRNA 
expressions caused by Aroclor 1260 exposure for (A) TNFα, (B) IL-6, (C) MCP2 
and (D) MIP1α. Values are mean ± SEM, p <0.05, a- ∆ due to HFD, b- ∆ due to 
Aroclor 1260 exposure at 20 mg/kg. CD-control diet, HFD-high fat diet, Ar-Aroclor 



















Aroclor 1260 induced hepatic CAR, PXR and AhR target genes 
PCBs are known activators of AhR and CAR, which are involved in 
xenobiotic detoxification (24, 96). Recent studies have demonstrated PCBs’ 
interaction with other nuclear receptors including human PXR and rodent 
peroxisome-proliferator activated receptor alpha (PPARα) (97-99). We 
hypothesized that Aroclor 1260 may interact with these receptors in our animal 
model. We therefore looked at the hepatic expression levels of these receptors’ 
target genes in all animal groups. 
The mRNA levels of Cyp2b10, a CAR target gene, were significantly up-
regulated in all Aroclor 1260-exposed groups (Fig. 2.10 A, p <0.05).  In the CD 
groups, the fold induction of Cyp2b10 was slightly higher in the lower dose (20 
mg/kg) as compared to the higher dose (200 mg/kg) (approximately 1000-fold vs. 
500-fold respectively). Feeding a HFD markedly reduced the fold induction of 
Cyp2b10 with inductions of 4.3-fold and 12-fold being observed at 20 mg/kg and 
200 mg/kg exposures, respectively. Thus the reduction in fold induction caused 
by HFD feeding vs. CD feeding at 20 mg/kg and 200 mg/kg was reduced by 
approximately 235-fold and 41-fold, respectively. These results appear consistent 
with previous studies (100, 101), and indicate that the ability of CAR to activate 
target genes is compromised when animals are fed with HFD. 
Hepatic Cyp3a11 (PXR target gene) expression levels were also 
significantly induced in all Aroclor 1260-exposed groups (Fig. 2.10 B, p <0.05). 
The Cyp3a11 fold induction caused by Aroclor 1260 exposure was significantly 
lower compared to Cyp2b10 (approximately 30- to 34-fold for the 20 mg/kg 
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exposure and 20- to 25-fold for the 200 mg/kg exposure). Contrary to Cyp2b10 
expression, HFD did not affect the fold inducibility of this particular gene. 
However, HFD feeding decreased the basal expression level of Cyp3a11 by 
approximately 8-fold.   
The mRNA levels of Cyp1a2 (AhR target gene) were also measured in all 
the groups to determine Aroclor 1260 activation of the AhR. Hepatic Cyp1a2 
expression was up-regulated in both dietary groups exposed to Aroclor 1260 only 
at 200 mg/kg (Fig. 2.10 C, p <0.05) but not at 20 mg/kg. Feeding with a HFD had 
no effect on either fold inducibility or basal level expression of this gene. These 
results suggest that with Aroclor 1260, the levels of congeners that activate 
CAR/PXR are present in much higher concentrations than those that activate 
AhR and the receptor based-effects of Aroclor 1260 at the lower dose are likely 
to be mediated primarily through CAR/PXR activation. 
In addition to direct targets, both CAR and PXR are capable of binding, 
potentially sequestering and altering the transcriptional activity of the 
transcription factor forkhead box O1 (FOXO1) (74).  FOXO1 is an important 
transcription factor controlling the expression of a wide range of gluconeogenic 
and lipogenic genes.  To examine if FOXO1 mediated gene transcription was 
being affected, we examined the effects of Aroclor exposure on PEPCK-1, a 
prototypical FOXO1 target gene and the rate limiting step in gluconeogenesis. 
HFD feeding did not affect PEPCK-1 mRNA levels alone but Aroclor 1260 














Figure 2.10. Aroclor 1260 exposure altered hepatic expression of CAR, PXR 
and AhR target genes. 
Real-time PCR experiments showed the changes in hepatic mRNA 
expressions caused by Aroclor 1260 exposure for (A) Cyp2b10 (CAR target 
gene), (B) Cyp3a11 (PXR target gene), (C) Cyp1a2 (AhR target gene) and (D) 
PEPCK-1 (an indirect target of CAR and PXR). Values are mean ± SEM, p 
<0.05, a- ∆ due to HFD, b- ∆ due to Aroclor 1260 exposure at 20 mg/kg, c- ∆ due 
to Aroclor 1260 exposure at 200 mg/kg. CD-control diet, HFD-high fat diet, Ar-


















Although several PCB mixtures were commercially produced and used 
widely (e.g. Aroclor(s) 1260, 1254, 1248, 1242 and 1016), Aroclor 1260 was 
selected for this study because of the similarity in its congener composition 
pattern to that in human fat (36). The major congeners in Aroclor 1260 are the 
high molecular weight PCBs that have either 5-, 6-, 7- or 8- chlorine substituents, 
which in turn results in di-ortho substitution, and hence are non-coplanar in 
structure. These high molecular weight PCBs are not well metabolized and 
therefore bio-accumulate in humans (35). PCB toxicity has been associated with 
cancer, endocrine disruption, and impaired cognitive development, but recent 
epidemiologic studies have shown that PCB exposures can also result in 
metabolic disorders associated with NAFLD, including obesity, insulin 
resistance/diabetes, and the metabolic syndrome (41, 42, 102). Occupational 
exposure to PCB mixtures has also been associated with elevated plasma levels 
of liver enzymes (18). Chronic exposures to these chlorinated compounds 
appear to disrupt both lipid and glucose homeostasis and consequently lead to 
diabetes and associated metabolic disorders. The current study investigated the 
effects of environmental pollutant-nutrient interactions, which is clinically relevant 
because all humans are exposed to PCBs and over 75% of the US adult 
population is considered to be either overweight or obese. Exposure to toxicants 
such as PCBs may act as a ‘second hit’ that eventually drives this population to 
steatohepatitis and the metabolic syndrome.  
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PCBs bio-accumulate in the liver and adipose tissue due to their 
hydrophobicity, thus, making these sites principal targets for PCB toxicity. Lipid-
adjusted serum PCB levels were measured in NHANES participants and in the 
PCB exposed Anniston cohort with the highest reported levels ranged from 75-
170 ng/g (18, 46). Additionally, the National Toxicology Program (NTP) studies 
measured PCB levels in a 2-year gavage study in rats. Interestingly, PCB liver 
levels were at least 10-fold higher and adipose levels were at least 200-fold 
higher than lipid-adjusted serum levels irrespective of the dose administered or 
treatment time (22). Although Aroclor 1260 levels were not measured in our 
study, we speculate that the distribution will be similar to other PCBs used in 
NTP studies. In those studies, a 20 mg/kg cumulative dose yielded the following 
levels: serum-176 ng/g, liver-3,663 ng/g and adipose-92,840 ng/g while a 200 
mg/kg cumulative dose yielded levels: serum-1,788 ng/g, liver-34,010 ng/g and 
adipose-1,118,300 ng/g. Thus the 20 mg/kg dose employed is expected to 
produce serum levels similar to the maximum levels reported for the Anniston 
cohort (170.4 ng/g). The 200 mg/kg dose is similar to that used in the NTP TR 
530 for cancer studies. In the present study, we exposed mice to PCBs using 
gavage which was designed to mimic human exposure routes. A potential caveat 
is that these mice received either a single exposure or four separate exposures 
rather than the intermittent exposures that humans encounter from eating PCB- 
contaminated food. We also attempted to have several weeks between exposure 
to PCBs and the measurement of study endpoints to maximize the effects from 
bio-accumulated PCBs rather than any metabolized congeners.      
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The main finding from this study was the Aroclor 1260-mediated transition 
of steatosis to steatohepatitis in the diet-induced obesity model. Paradoxically, 
NASH was associated with decreased % fat composition and increased lean 
body mass at the low dose exposure (Fig. 2.2). Additionally, CD groups showed 
a decrease in body weight gain which may be attributed to stress experienced 
due to oral gavage. None of the CD groups exposed to Aroclor 1260 manifested 
hepatitis (H&E staining). Contrarily, Aroclor 1260 exposure in HFD groups 
worsened liver necro-inflammation (Fig. 2.3). Co-exposure to HFD and Aroclor 
1260 (20 mg/kg) resulted in elevated serum ALT, IL-6 and tPAI-1 and 
upregulated hepatic TNFα expression (Fig. 2.5). However, Aroclor 1260 at 200 
mg/kg did not induce systemic inflammation, despite histologic signs of liver 
injury.  
The results from this study differed markedly from our earlier work on a 
single congener, PCB 153, where HFD+PCB 153 co-exposure worsened 
steatosis and obesity in male C57Bl/6J mice without causing inflammation (48). 
We documented PCB 153-mediated adipokine dysregulation; a phenomenon 
which was absent in the current study. Furthermore, HFD+PCB 153 co-exposure 
altered hepatic expression of genes involved in fatty acid metabolism including 
increased FAS and decreased CPT1A mRNA expression. Although PCB 153 is 
present in Aroclor 1260, other congeners are present in this PCB mixture that 
may contribute to steatohepatitis and yet have no effect on obesity. Thus, 
exposing animals to a mixture can yield outcomes that are entirely different from 
that of a single congener.  
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Hepatic P450s, including Cyp3a11 (PXR target) and Cyp2b10 (CAR 
target), were induced by Aroclor 1260 exposure in both CD and HFD-fed mice 
(Fig. 2.10). PXR and CAR are critically involved in xenobiotic metabolism and 
drug disposition, but recent studies demonstrated the importance of CAR and 
PXR regulation on physiological processes such as glucose and lipid 
metabolism, and this could impact NASH (60, 103, 104). Gao et al. demonstrated 
CAR as an anti-obesity receptor whose activation was protective against diet-
induced obesity and insulin resistance (72). On the contrary, the role of PXR in 
obesity remains controversial with studies reporting either anti-obesity or obesity 
promoting effects (75, 77, 105). Our RT-PCR data strongly suggest CAR 
activation by Aroclor 1260 as indicated by the ~1000- to 500-fold induction of 
Cyp2b10 at both the low and high exposure levels. Cyp3a11 induction is a 
hallmark of PXR activation, but activated CAR can also bind to the Cyp3a11 
response element and drive its expression, albeit, at lower levels. Although 
Cyp3a11 was induced by ~30-fold, this induction may be mediated by CAR 
rather than PXR. These results indicate that Aroclor 1260 exposure activated 
CAR/PXR, hence the possible obesity-protective effects seen in the HFD-fed 
mice exposed to Aroclor 1260.  
Furthermore, CAR/PXR activation suppresses FOXO1-insulin response 
sequence (IRS) binding activity (Kodama et al., 2004) resulting in decreased 
gluconeogenesis and hence the lowered fasting blood glucose levels seen in 
CD+Aroclor 1260 groups (Fig. 2.6). Additionally, FOXO1, is a negative regulator 
of SREBP1 transcription and its sequestration by activated CAR/PXR could 
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result in increased SREBP1 gene expression (74, 106). Notably in our study, 
hepatic SREBP-1c expression was induced in HFD-fed mice exposed to Aroclor 
1260. However, activated CAR and PXR can transcriptionally activate the anti-
lipogenic gene Insig, consequently leading to reduced SREBP1 activity and 
decreased SREBP1 target gene expression such as FAS (73). Hence, the 
decrease in FAS expression observed in this study could possibly be due to loss 
of SREBP1 activity even though the gene was induced.  Additionally, CD36, a 
lipid scavenger receptor and target gene shared by AhR, PXR and LXR was also 
induced by Aroclor 1260 (Fig. 2.7). Other novel findings in this study included 
induction of CPT1A and decreased hepatic FAS expression with Aroclor 1260 
exposure in HFD-fed mice. In concert, the effects of Aroclor 1260 on lipogenesis 
appeared complex, and interactions with CAR/PXR could contribute to the 
observed decrease in % fat composition in HFD+Aroclor 1260 groups. Moreover, 
glucose metabolism was abnormal in HFD-fed mice exposed to Aroclor 1260 
(200 mg/kg), because, while HOMA-IR was lowered, glucose tolerance failed to 
improve. It appears that HOMA-IR and glucose tolerance test may be insufficient 
to evaluate glucose metabolism in PCB studies, given the partially divergent 
effects of PCB exposure in the fed and fasted state. However, these 
observations need to be pursued further to elucidate the mechanisms involved.  
Regardless of Aroclor 1260 exposure, it appeared that HFD consumption 
reduced the induction of CAR/PXR target genes as compared to CD 
consumption and it was only HFD-fed mice exposed to Aroclor 1260 that 
exhibited liver injury. Therefore, it is plausible to say that activation of xenobiotic 
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receptors such as CAR/PXR protect against PCB toxicity in a low fat diet setting. 
Therefore HFD consumption interferes with CAR/PXR activation by PCBs, and 
therefore attenuates the protective effects of these receptors against PCB toxicity 
with the net result being increased liver injury only in Aroclor 1260+HFD co-
exposed animals. The progression of NAFLD from simple steatosis to 
steatohepatitis requires both hepatic fat accumulation and inflammation. In this 
study, it was observed that in steatotic mice exposed to low dose Aroclor 1260, 
inflammation and liver injury was aggravated, while at the high dose, 
inflammation was suppressed and liver injury was attenuated. Our results 
suggest that it is the inflammatory dysfunction that PCBs induce rather than the 
degree of steatosis observed that may dictate appearance of steatohepatitis. 
Hepatic expression of Cyp1a2 (AhR target gene) was induced only in 
groups receiving Aroclor 1260 at the highest dose tested (Fig. 2.10), suggesting 
dose-dependent activation of this receptor. AhR activation by PCBs is well 
documented with coplanar (‘dioxin-like’) PCBs including PCB 126 being good 
rodent AhR activators. A wasting syndrome and chloracne are characteristic 
features of AhR activation by its classic ligand TCDD (107). AhR activation is 
also associated with immune suppression via AhR interference with NF-κB 
signaling (108). Consistent with these results, animals exposed to Aroclor 1260 
(200 mg/kg) displayed lower body weight and a suppression of serum pro-
inflammatory cytokines and resistin levels (Fig. 2.5). Resistin, also known as the 
adipocyte secretory factor, is secreted by the adipose tissue and appears to 
participate in inflammatory processes as well (109). While reduced body weight 
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has frequently been reported with animals exposed to AhR ligands, in murine 
and human models, steatosis increases, presumably due to a redistribution of 
dietary fat (110). Thus activation of the AhR may lead to increased steatosis but 
decreased steatohepatitis, as a function of its immunosuppressive effects. The 
activation AhR by Aroclor 1260 is likely due to the presence of coplanar 
congeners such as PCB 126 but these compounds exist in relatively low 
percentages in this mixture (<1%), and hence a higher Aroclor 1260 exposure 
level is required to observe the ‘dioxin-like’ effects. Therefore, absence of 
inflammation at the higher dose may be due to the immune-suppressive 
properties of activated AhR. 
Thus, we identified both CAR/PXR and AhR activation as potential 
mode(s) of action of this PCB mixture in NASH. Nonetheless, rodent and human 
receptors may have differences pertaining to ligand binding activity and target 
gene battery. Off target effects are also possible mechanisms in PCB-driven 
NASH, but these were not evaluated in this study. Moreover, the current study 
failed to distinguish between CAR and PXR activation which is a potential 
drawback since the observed Aroclor 1260 effects may be based solely on CAR 
activation. Thus further investigation to distinguish between the CAR an d PXR-
mediated effects using PXR/CAR knockout models is required. The study also 
failed to assess overall metabolism and employing metabolic chambers would 
have been useful in this regard. Furthermore, another drawback in this study was 
using serum ALT/AST as a NASH biomarker based on low sensitivity, and 
evaluating other biomarkers is a possibility in future studies (50). In addition, our 
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studies were performed using male mice; hence it is pertinent to note that the 
observed effects may vary with gender and species.  
In conclusion, Aroclor 1260 exposure caused toxicant-associated 
steatohepatitis in animals fed with HFD. In contrast to our previous study wherein 
a single congener (PCB 153) was used, this PCB mixture neither increased the 
body weight/visceral adiposity nor worsened insulin resistance/diet-induced 
obesity. There was a significant difference between the low and high exposure 
doses in terms of hepatic/systemic inflammation, which could potentially be due 
to AhR activation. Our additional findings demonstrate that Aroclor 1260 
activated CAR and PXR and to a lesser extent AhR, suggesting congener 
composition and exposure levels to be critical in determining a mixture’s mode(s) 
of actions. Lastly, CAR and PXR activation could be protective against PCB-
mediated toxicity but HFD consumption may blunt this protection. More studies 













EVALUATING THE ROLE OF CAR AND PXR IN AROCLOR 1260-INDUCED 
LIVER INJURY 
INTRODUCTION 
Our initial studies in a diet-induced obesity mouse model demonstrated 
that Aroclor 1260 exposure had modest effects on a control diet but induced 
steatohepatitis when animals were fed with a high fat diet. In animals fed a high 
fat diet, Aroclor 1260 exposure did not exacerbate obesity. However, in the liver, 
Aroclor 1260 exposure (20 mg/kg) activated nuclear receptors, including CAR 
and PXR as the cytochrome P450s, namely, Cyp2b10 and Cyp3a11 were 
robustly induced.  At higher Aroclor 1260 exposures (200 mg/kg), the AhR was 
also activated. Furthermore, PCB activation of the AhR has been well studied 
and its activation has been linked to hepatic cancer. However PCB activation of 
CAR and PXR and the subsequent contribution of these activated receptors to 
PCB effects and toxicity have not been thoroughly evaluated, especially in terms 
of obesity and NAFLD/NASH. 
In this study, the role of CAR and PXR in Aroclor 1260-induced liver injury 
was further characterized. We hypothesized that CAR and PXR play a role in the 
transition of steatosis to steatohepatitis caused by Aroclor 1260 exposure. The 
CAR and PXR knockout mouse models were utilized to demonstrate that both 
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receptors were required for normal physiology and that they both played a 
protective role in PCB+HFD-induced liver disease. Additionally, in the previous 
study, mice receiving Aroclor 1260 at 20 mg/kg elicited CAR and PXR activation 






















MATERIALS AND METHODS 
Animals and diets 
The animal protocol was approved by the University of Louisville 
Institutional Animal Care and Use Committee. Wild type male C57Bl/6J mice 
(WT, 8 weeks old; The Jackson Laboratory, Bar Harbor, ME, USA) and CAR-/- 
and PXR-/- mice (Taconic, Hudson, NY) were divided into 6 study groups (n=10) 
based on Aroclor 1260 exposure utilizing a 2x3 design. All mice were fed a high 
fat diet (HFD, 42% kCal from fat; TD.88137 Harlan Teklad) in this 12 week study. 
On Week 1, Aroclor 1260 (AccuStandard, CT, USA) was administered in corn oil 
by oral gavage (vs. corn oil alone) at 20 mg/kg. This dose was designed to mimic 
the maximum human PCB exposures seen in the PCB-exposed Anniston cohort. 
Mice were housed in a temperature- and light controlled-room (12 hour light; 12 
hour dark) with food and water ad libitum. During Week 8-9, mice were placed in 
metabolic chambers (PhenoMaster, TSE systems, Chesterfield, MO) overnight to 
assess food/drink consumption and physical activity. A glucose tolerance test 
was performed at Week 11, and the animals were euthanized (ketamine/ 
xylazine, 100/20 mg/kg body weight, i.p.) at the end of Week 12. Prior to 
euthanasia, the animals were analyzed for body fat composition by dual energy 
X-ray absorptiometry (DEXA) scanning (Lunar PIXImus densitometer, WI, USA). 
Thus six different groups were evaluated; WT, WT+Aroclor 1260, CAR-/-, CAR-/-
+Aroclor 1260, PXR-/-, PXR-/-+Aroclor 1260. 
Glucose tolerance test 




See detailed method in Chapter 2. 
Cytokine and adipokine measurement 
See detailed method in Chapter 2. 
Measurement of hepatic triglyceride and cholesterol content 
See detailed method in Chapter 2. 
Real-time PCR 
See detailed method in Chapter 2. Additional primer sequences from 
Taqman Gene Expression Assays (Applied Biosystems, Foster City, CA) that 
were utilized in the current study included UDP glucuronosyltransferase 1 family, 
polypeptide A1 (Ugt1a1); (Mm02603337_m1), patatin-like phospholipase domain 
containing 2 (PNPLA2); (Mm00503040_m1), PXR (Mm01344139_m1), CAR 
(Mm01283978_m1), fatty acid binding protein-1 (FABP1); (Mm00444340_m1), 
glucokinase (Gck); (Mm00439129_m1), GLUT-2, (Mm00446229_m1), GLUT-4 
(Mm01245502_m1), glucose-6-phosphatase (G6Pase); (Mm00839363_m1), 
Insig-1 (Mm00463389_m1) and Insig-2 (Mm01308255_m1). 
Immunoblots 
Frozen liver samples (0.1 g) were homogenized in 0.5 mL radio-
immunoprecipitation assay (RIPA) buffer (20 mM Tris, pH 7.4, 150 mM NaCl, 1 
mM EDTA, 1 mM EGTA, 1 mM β-glycerophosphate, 1 mM sodium vanadate, and 
1% w/w Triton X-100 w/v) containing 1 mM phenylmethylsulphonyl fluoride, 
protease and phosphatase (tyrosine and serine/threonine) inhibitor cocktails 
(Sigma Aldrich, St. Louis, MO, USA). Lysates were sonicated at 4 °C for 4 h and 
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subsequently centrifuged for 5 minutes at 16,000 g. The protein concentration of 
the supernatants was determined using the Bicinchoninic Acid Protein Assay Kit 
(Sigma Aldrich). Total protein was diluted in RIPA buffer and mixed with sample 
loading buffer [250 mM Tris, pH 7.4, 10% sodium dodecyl sulfate (SDS), 20% β-
mercaptoethanol w/v, 40% glycerol, and 0.05% bromophenol blue] and incubated 
at 95 °C for 5 minutes. The samples were loaded onto SDS-polyacrylamide gels 
(Bio-Rad Laboratories, Hercules, CA, USA), followed by electrophoresis and 
Western blotting onto polyvinylidene difluoridemembranes (Immobilon-P; 
Millipore Corp, Billerica, MA, USA). Antibodies against the sterol regulatory 
element binding protein 1 (SREBP1, Abcam, Cambridge, MA, USA), AMP-
activated protein kinase α (AMPKα, Cell Signaling Technology, Danvers, MA, 
USA), phospho-AMPKα (p-AMPKα, Cell Signaling Technology), mammalian 
target of rapamycin (mTOR, Cell Signaling Technology), phospho-mTOR (p-
mTOR, Cell Signaling Technology) and β-actin (Santa Cruz Biotechnology, 
Dallas, TX, USA) were used at dilutions recommended by the suppliers. 
Horseradish peroxidase-coupled secondary antibodies were obtained from 
Abcam and Cell Signaling Technology. Chemiluminescence detection was 
performed using the Pierce ECL2 western blotting substrate reagents (Thermo 
Scientific, Wilmington, DE, USA). Densitometric quantitation was performed with 
the Image Lab software (Bio-Rad Laboratories). 
Statistical Analysis 
Statistical analyses were performed using SigmaPlot version 11.0 (Systat 
Software, Inc., San Hose, CA, USA). Data are expressed as mean ± SEM. 
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Multiple group data were compared using Two Way ANOVA followed by Tukey 






















Effects of CAR and PXR on bodyweight and adiposity 
Bodyweight was measured weekly throughout the 12-week study (Fig. 3.1 
A). All groups experienced bodyweight gain until Week 11. The bodyweight drop 
was possibly due to stress caused by the glucose tolerance test that was 
performed on Week 11. Aroclor 1260 exposure had no significant effect on the 
percent (%) increase in bodyweight gain calculated in the WT or PXR-/- groups 
(Fig. 3.1 B). However, the CAR-/- mice exposed to Aroclor 1260 showed a lower 
% increase in the bodyweight gain than any other group. The % body fat 
composition was evaluated by DEXA scanning prior to harvesting the tissues 
(Fig. 3.1 C). Because all groups were on HFD feeding, the average % body fat 
composition among the animals was ~40%. However, the PXR-/- groups 
displayed significantly higher % body fat composition with or without Aroclor 1260 
exposure. The PXR-/- groups also showed significantly lower lean body mass (g), 
irrespective of Aroclor 1260 exposure (Fig. 3.1 D). The liver to bodyweight ratio 
(LW/BW) was calculated and the PXR-/- groups showed significantly higher liver 
mass and LW/BW when compared to any other group (Fig. 3.1 E).  
The epididymal fat sections were stained with H&E (Fig. 3.2 A) and the 
adipocyte size was measured using Image J software (Fig. 3.2 B). The mean 
adipocyte size (µm2) was lower in the CAR-/- groups irrespective of Aroclor 1260 
exposure. There was no difference in the adipocyte size in the WT or PXR-/- mice 
irrespective of Aroclor 1260 exposure. Ad libitum food consumption per mouse 
per day (g) was calculated over the 12-week period of the study (Fig. 3.2 C). 
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There was a drop in the food consumption rate on Week 2 for all groups possibly 
due to the corn oil gavage. During the study period, the CAR-/- and PXR-/- mice 
exposed to Aroclor 1260 showed relatively lower food consumption rate while the 




























Figure 3.1. Effects of Aroclor 1260 exposure on body weight and visceral 
adiposity in CAR-/- and PXR-/- mice. 
 (A) Increase in body weight with time for C57BL/6 (WT), CAR-/- and PXR-/- 
mice (n=10) fed with a 42% milk fat diet. Body weight measurements were taken 
weekly from Week 1 to Week 12. (B) The % increase in body weight gain with 
time was calculated and the body weight at Week 1 was taken as 100%. (C) % 
fat composition and (D) lean tissue mass (g) were measured using the DEXA 
scanner. PXR knockout mice demonstrated a higher % fat composition and 
lowered lean tissue mass vs. WT and CAR-/- groups. (E) Livers were removed 
and weighed at euthanasia and the liver to bodyweight ratio was calculated. 
Values are mean ± SEM, p <0.05, *- ∆ due to Aroclor 1260 exposure, # - ∆ due 
















Figure 3.2. Effects of Aroclor 1260 exposure on the adipocyte size and food 
consumption in CAR-/- and PXR-/- mice. 
(A) The epididymal adipose tissue was stained with H&E. (B) Adipocyte 
size (µm2) was measured and average cell size of >100 cells for each group was 
calculated. (C) Food consumption per mouse per day (g) was measured 
throughout the 12 week period. Values are mean ± SEM, p <0.05, * - ∆ due to 












Metabolic chamber studies  
Animals were placed in metabolic cages at the beginning of Week 8 for 
metabolic assessment. Oxygen consumption (vO2) and carbon dioxide 
production (vCO2) were monitored and the respiration exchange rate (RER, 
vCO2/vO2) was calculated. The measured ratio (RER) was used to estimate the 
respiratory quotient which indicates whether the fuel source/energy expenditure 
is from carbohydrate or lipid metabolism. An RER of 0.70 suggests that fat is the 
predominant fuel source (oxidation of a molecule of fatty acid: 23 O2 + C16H32O2 
→ 16 CO2 + 16 H2O + 129 ATP, RER = vCO2/vO2 = 16 CO2/23 O2 = 0.7), 
whereas an RER of 0.85 indicates a mix of fat and carbohydrates. An RER of 
1.00 or above is indicative of carbohydrate being the predominant fuel source 
(oxidation of a molecule of carbohydrate: 6 O2 + C6H12O6 → 6 CO2 + 6 H2O + 38 
ATP, RER = vCO2/vO2 = 6 CO2/6 O2 = 1.0) and this usually occurs during intense 
physical activity such as exercise.  
The knockout groups that were unexposed to Aroclor 1260 showed a 
lower RER (~0.70), indicating a lipid-driven energy breakdown (Fig. 3.3 A). The 
RER was increased with Aroclor 1260 exposure in the knockout groups in both 
the light and dark cycle, indicating a mix of fat and carbohydrate fuel source. 
There was no difference in the RER in WT mice with or without Aroclor 1260 
exposure. The total energy expenditure (EE) was computed using the following 
modified Weir equation: EE = (3.815 + 1.232 x RER) x VO2 (111). There were no 
differences in the EE between the groups (Fig. 3.3 B). 
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 Movement/physical activity was also assessed using the metabolic 
chambers. The CAR and PXR knockout mice exposed to Aroclor 1260 showed 
increased movement/physical activity during the light cycle relative to the 
unexposed knockout mice (Fig. 3.4 A). Furthermore, the CAR-/- group exposed to 
Aroclor 1260 demonstrated significantly lower food and drink consumption in the 





















Figure 3.3. Assessment of respiration exchange rate and energy 
expenditure utilizing metabolic cages. 
Four mice from each group were taken randomly and placed in metabolic 
cages for 24 h (12 h light and 12 h dark cycle). (A) The respiration exchange rate 
(RER) which is the ratio of CO2 exhaled to O2 consumed was calculated as an 
indicator of energy expenditure. (B) The total energy expenditure (EE, kCal/kg/h) 
was calculated using the values obtained from RER and VO2. Values are mean ± 
SEM, p <0.05, * - ∆ due to Aroclor 1260 exposure, # - ∆ due to knocking out 




















Figure 3.4. Assessment of movement, food and drink consumption utilizing 
metabolic cages. 
Four mice from each group were taken randomly and placed in metabolic 
cages for 24 h (12 h light and 12 h dark cycle). (A) Physical activity was 
measured using infrared beams and sensors. The total movement (counts) which 
is the sum of ambulatory movement (mouse crosses two adjacent beams) and 
fine movement (mouse crosses the same beam twice) was calculated. The 
average amount of (B) food (g)/day and (C) water (mL)/day consumed per group 
was measured. Values are mean ± SEM, p <0.05, * - ∆ due to Aroclor 1260 









The role of CAR and PXR in Aroclor 1260-induced liver injury and steatosis 
All animal groups developed steatosis by the end of the study due to high 
fat feeding. Histological examination of liver sections demonstrated that Aroclor 
1260 exposure induced liver injury in all groups of mice and this injury was 
independent of the presence of CAR or PXR (Fig. 3.5 A). Scattered inflammatory 
foci and neutrophil infiltration were also observed with CAE staining and these 
foci were more pronounced in the PXR-/- mice exposed to Aroclor 1260 (Fig. 3.5 
B). Although exposure to Aroclor 1260 caused liver injury (H&E and CAE 
staining), serum ALT was not significantly elevated (Fig. 3.5 C). Furthermore, 
serum AST was unaffected in all groups (Fig. 3.5 D).  
Hepatic levels of triglycerides and cholesterol were quantified to measure 
the degree of steatosis and there were no significant differences in hepatic lipids 
among the groups (Fig. 3.5 E&F). This was somewhat surprising as the PXR-/- 















Figure 3. 5. Aroclor 1260 exposure caused steatohepatitis in WT, CAR-/- and 
PXR-/- mice. 
 (A) H&E staining of hepatic sections established the occurrence of 
centrilobular hepatocellular hypertrophy, karyomegaly, and multinucleate 
hepatocytes in the Aroclor 1260-exposed groups. High fat diet consumption 
resulted in variable, centrilobular, microvesicular lipidosis while mice exposed to 
Aroclor 1260 exhibited occasional, small areas of necrosis and inflammation 
(steatohepatitis). (B) CAE staining demonstrated neutrophil infiltration in the 
Aroclor 1260-exposed groups. (C). Serum ALT and (D) AST levels (U/L) were 
measured (n=10) using the Piccolo Xpress chemical analyzer. Hepatic levels of 
(E) cholesterol and (F) triglycerides were quantified (µg/mg tissue) in mice (n=10) 
fed with HFD with or without Aroclor 1260 co-exposure. Values are mean ± SEM, 
p <0.05, * - ∆ due to Aroclor 1260 exposure, # - ∆ due to knocking out CAR or 











CAR and PXR are protective against Aroclor 1260-induced hepatic and 
systemic inflammation 
To further assess the role of nuclear receptors in Aroclor 1260-induced 
steatohepatitis, hepatic expression of toll like receptor 4 (TLR-4) target genes 
including tumor necrosis factor alpha (TNFα), interleukin 6 (IL-6), monocyte 
chemo-attractant protein 2 (MCP2) and monocyte inducible factor 1 alpha 
(MIP1α) were measured using RT-PCR. Aroclor 1260 exposure resulted in 
increased TNFα expression in the liver of WT mice (Fig. 3.6 A). Interestingly, the 
basal expression of TNFα in the knockout mice was higher than in the WT mice, 
regardless of Aroclor 1260 exposure. The CAR-/- mice with or without Aroclor 
1260 exposure showed significantly higher TNFα mRNA levels when compared 
to any other group. Likewise, the basal expression of hepatic IL-6 was also 
higher in the knockout groups than the WT group (Fig. 3.6 B).  PXR-/- mice 
exposed to Aroclor 1260 showed the highest hepatic IL-6 mRNA levels among all 
groups. Hepatic expression of MCP2 and MIP1α were not significantly different 
between the groups (Fig. 3.6 C&D). Overall, it appeared that knocking out CAR 
and PXR increased hepatic TNFα and IL-6 expression, irrespective of Aroclor 
1260 exposure. 
Serum cytokines, namely, TNFα, IL-2, interferon gamma (IFNγ), IL-17, 
MCP1 and MIP-1α were measured using the Luminex IS system. Similar to 
hepatic TNFα expression, serum TNFα levels were higher in Aroclor 1260-
exposed WT-mice compared to unexposed mice in the WT group (Fig. 3.7). 
However, there was no significant difference in serum TNFα levels in the Aroclor 
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1260-exposed compared to unexposed mice in the knockout groups. Likewise, 
serum IL-2 and IFNγ were also increased in the Aroclor 1260-exposed when 
compared to unexposed mice in the WT group but there was no difference 
observed in the knockout groups. Notably, the basal levels of serum TNFα and 
IL-2 were higher in the PXR-/- group, irrespective of Aroclor 1260 exposure. There 






















Figure 3.6. Effects of Aroclor 1260 exposure on the TLR-4 target genes in 
CAR-/- and PXR-/- mice. 
Real-time PCR experiments showed the changes in hepatic mRNA 
expression caused by Aroclor 1260 exposure and knocking out CAR or PXR for 
(A) TNFα, (B) IL-6, (C) MCP2 and (D) MIP1α. Values are mean ± SEM, p <0.05, 




























Figure 3.7. Effects of Aroclor 1260 exposure on serum cytokines in CAR-/- 
and PXR-/- mice. 
Serum TNFα (pg/mL), IL-2 (pg/mL), IFNγ (pg/mL), IL-17 (pg/mL), MIP1α 
(pg/mL) and MCP1 (pg/mL) levels were measured using the Luminex IS 100 
system (n=10). Values are mean ± SEM, p <0.05, * - ∆ due to Aroclor 1260 









Aroclor 1260, CAR and PXR regulation in glucose metabolism and insulin 
resistance 
Fasting blood glucose levels were measured prior to performing the 
glucose tolerance test. There were no differences in fasting blood glucose levels 
between the six groups (Fig. 3.8 A). Glucose tolerance test was then performed 
and the area under the curve (AUC) was calculated to measure the degree of 
glucose uptake and clearance in the fed state (Fig. 3.8 B&C). Aroclor 1260 
exposure had no effect on GTT (AUC) in WT and CAR-/- groups. In contrast, 
Aroclor 1260 exposure caused an increase in the GTT (AUC) in PXR-/- mice.  
Insulin resistance was calculated by homeostasis model assessment 
using the formula: homeostasis model assessment of insulin resistance (HOMA-
IR)=Fasting glucose (mg/dL) x Fasting insulin (µU/mL)/405.  HOMA-IR was 
calculated to determine if CAR and PXR played a role in high fat diet-induced 
insulin resistance, a common hallmark of non-alcoholic fatty liver disease (Fig. 
3.8 D). Aroclor 1260 exposure significantly decreased HOMA-IR in WT, CAR-/- 
and PXR-/- groups, although fasting blood glucose levels were not decreased. 
The reduction in HOMA-IR was due to lower serum insulin levels in all groups 
exposed to Aroclor 1260 (Fig. 3.8 E). These results indicated that Aroclor 1260 
exposure resulted in impaired insulin production and thus, although GTT (AUC) 
was unchanged, HOMA-IR was decreased. Insulin sensitivity was assessed 
using the quantitative insulin sensitivity check index (QUICKI) as follows: 
QUICKI=1 / (log (fasting insulin µU/mL) + log (fasting glucose mg/dL)). 
Interestingly, the Aroclor 1260-exposed, PXR knockout group showed a 
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significantly higher index for insulin sensitivity, indicating a significant interaction 
between Aroclor 1260 exposure and PXR ablation (Fig. 3.8 F). 
Furthermore, to assess gluconeogenesis, the hepatic expression of the 
CAR/PXR indirect targets, phosphoenol-pyruvate carboxykinase 1 (PEPCK-1) 
and glucose-6-phosphatase (G6Pase) were measured (Fig.3.9 A&B). Hepatic 
PEPCK-1 m RNA levels were not affected with Aroclor 1260 exposure in the WT 
group. However, Aroclor 1260 exposure in the knockout groups induced PEPCK-
1 and this induction was highest in the PXR-/- group, which may explain the 
increase in fed-state glucose levels as indicated by the GTT (AUC). Additionally, 
the PXR knockout mice exposed to Aroclor 1260 also showed significantly higher 
G6Pase expression in the liver. These data indicated that the gluconeogenic 
pathway was switched on in this group of mice, thus causing an increase in GTT 
(AUC). 
Hepatic expression of the glycolytic enzyme glucokinase (Gck) was 
induced only in the CAR knockout mice exposed to Aroclor 1260 but not in the 
WT mice (Fig.3.9 C). This could potentially explain the increase in RER with 
Aroclor 1260 exposure in the CAR knockout groups. Hepatic expression of the 
glucose transporter GLUT-2 was increased with Aroclor 1260 exposure in the 
WT and CAR knockout groups but the induction by Aroclor 1260 was lost in the 
PXR knockout group (Fig. 3.9 D). On the other hand, the basal expression of the 
insulin-dependent glucose transporter, GLUT4 was higher in the CAR knockout 










Figure 3.8. Effects of Aroclor 1260, CAR and PXR in glucose metabolism 
and insulin resistance. 
 (A) Fasting blood glucose levels (mg/dL) were measured and (B) glucose 
tolerance test was performed. Blood glucose levels were measured for mice 
(n=10) fed with high fat diet with or without Aroclor 1260 co-exposure. (C) AUC 
was calculated, and the PXR knockout mice exposed to Aroclor 1260 showed 
higher AUC levels vs. unexposed group and WT exposed mice. (D) Homeostasis 
model assessment of insulin resistance (HOMA-IR) was calculated from fasting 
blood glucose and insulin levels for all six groups of animals (n=10). (E) Serum 
insulin levels were measured using the Luminex IS 100 system. (F) Quantitative 
insulin sensitivity check index (QUICKI) which is an index for insulin sensitivity 
was calculated. Values are mean ± SEM, p <0.05, * - ∆ due to Aroclor 1260 


















Figure 3.9. Effects of Aroclor 1260, CAR and PXR on genes involved in 
glucose metabolism. 
Hepatic (A) PEPCK-1, (B) G6Pase, (C) glucokinase, (D) GLUT-2 and (E) 
GLUT-4 mRNA levels were quantified by RT-PCR. Values are mean ± SEM, p 





















CAR and PXR ablation altered serum adipokine levels 
Serum adipokines were measured to evaluate the effects of knocking out 
CAR/PXR on the adipose tissue. Serum leptin levels were not changed with 
either Aroclor 1260 exposure or by knocking out CAR/PXR. In contrast, serum 
adiponectin levels were increased in the knockout mice, regardless of Aroclor 
1260 exposure, leading to a decreased leptin/adiponectin ratio in the knockout 
mice (Fig.3. 10 A). This finding was consistent with the decreased adiposity 
observed in the CAR knockout group. However, the decreased leptin/adiponectin 
ratio was a paradoxical finding in the PXR knockout groups because the mice in 
these groups did not show a decrease in adiposity. Serum tissue plasminogen 
activator inhibitor-1 (tPAI-1) levels were not changed between the groups (Fig. 
3.10 B). Serum lipids were also measured, including cholesterol and triglycerides 
(Fig. 3.10 C&D). Serum cholesterol levels were higher in the unexposed, PXR 















Figure 3.10. CAR/PXR knockout mice demonstrated altered serum 
adipokine levels. 
(A) Serum leptin (pg/mL) and adiponectin (pg/mL) were measured using 
the Luminex IS 100 system and the leptin to adiponectin ratio was calculated. (B) 
Serum tPAI-1 levels were measured using the Luminex IS 100 system. Serum 
(C) cholesterol and (D) triglycerides were quantified with the Piccolo Xpress 
chemical analyzer.  Values are mean ± SEM, p <0.05, * - ∆ due to Aroclor 1260 


















Aroclor 1260, CAR and PXR modulated hepatic lipid metabolism and 
energy expenditure  
Liver-X-receptor alpha (LXRα) is a key transcription factor in lipid 
synthesis and cholesterol metabolism and its over-activation can promote or 
worsen steatosis. In the previous study, we demonstrated that Aroclor 1260 
exposure modulated hepatic fat metabolism by either upregulation or 
downregulation of genes involved in fatty acid synthesis and breakdown. 
Moreover, CAR and PXR can bind to the direct repeat 4 (DR-4) elements which 
are similar to the response elements that LXRα binds to in the promoter regions 
of target genes. Therefore, looking at LXRα target genes in this study may 
determine if crosstalk between these three receptors is a significant interaction 
altering steatosis.  
The hepatic expression of fatty acid synthase (FAS), a classic LXRα target 
gene was decreased with Aroclor 1260 exposure in WT mice (Fig. 3.11 A). In 
contrast, FAS mRNA levels were up-regulated in the PXR knockout groups with 
or without Aroclor 1260 exposure. Similar to FAS, the expression levels of 
stearoyl coenzyme A desaturase1 (SCD1), another LXRα target gene, was 
decreased with Aroclor 1260 exposure in the WT group (Fig. 3.11 B). However, 
SCD1 expression was upregulated in the CAR knockout groups with or without 
Aroclor 1260 exposure.  
The hepatic expression of CD36, a fatty acid binding protein and a 
common target gene of LXRα, PXR, AhR and PPARγ, was also assessed (Fig. 
3.11 C). Interestingly, Aroclor 1260 exposure resulted in an increase in CD36 
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expression in the WT group compared to the unexposed mice. The PXR-/- groups 
showed relatively higher basal CD36 mRNA levels than any other group and 
Aroclor 1260 exposure significantly induce CD36 in PXR-/- mice. The hepatic 
expression of the fatty acid binding protein 1 (FABP1), another protein required 
for fatty acid uptake and transport across the cell membrane was increased in 
the CAR knockout groups and the exposed, PXR knockout group (Fig. 3.11 D). 
Additionally, apart from the LXRα target genes that are involved in fat synthesis, 
hepatic expression of the lipolytic gene, papatin like phospholipase domain 
containing 2 (PNPLA2) was measured. Aroclor 1260 had no effect on PNPLA2 
expression in WT mice (Fig. 3.11 E). However, Aroclor 1260 exposure induced 
PNPLA2 in CAR-/- mice. In contrast, Aroclor 1260 exposure did not induce 
PNPLA2 in PXR-/- mice but the basal levels of PNPLA2 expression were 
elevated.  
The sterol regulatory element binding protein (SREBP-1c) is a 
transcription factor required for fatty acid biosynthesis and another transcriptional 
regulator for lipogenic genes including FAS and SCD1. SREBP-1c cleavage to its 
active form and subsequent translocation to the nucleus is controlled by many 
factors. One of these factors is CAR and PXR inhibition of SREBP-1c cleavage 
to its active form in the endoplasmic reticulum through the anti-lipogenic gene, 
Insig (73). Insig binds to the SREBP cleavage activating protein (SCAB) and 
prevents the cleavage of the SREBP precursor protein to its active form (112). 
We hypothesized that CAR and PXR would induce Insig and subsequently inhibit 
SREBP-1c cleavage to its active form (Fig. 3.12 A). Hepatic expression of 
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SREBP-1c was analyzed and the PXR-/- mice exposed to Aroclor 1260 exhibited 
higher SREBP-1c mRNA levels (Fig. 3.12 B). Hepatic expression of Insig-1 and 2 
isoforms were therefore measured. Insig-1 mRNA levels were lower in the 
Aroclor 1260 exposed mice in the WT and PXR knockout groups (Fig. 3.12 C). 
Interestingly, CAR and PXR ablation also lowered Insig-1 hepatic expression. In 
contrast, Insig-2 expression levels did not differ among the groups (Fig. 3.12 D). 
To further investigate the underlying mechanisms that resulted in decreased 
lipogenic gene expression (FAS, SCD1) in the exposed WT group but not in the 
knockout groups, we measured the protein levels of SREBP1 in the mouse liver 
(Fig. 3.12 E&F). Contrary to our hypothesis, CAR and PXR activation by Aroclor 
1260 in the WT group did not result in lowered active SREBP1 isoform. Rather, 
Aroclor 1260 exposure caused an increase in SREPB1 cleavage from the 
inactive, precursor form that binds to the SREBP cleavage activating protein 
(SCAB)-Insig complex. 
 However, as mentioned before, SREBP1 transcriptional activity is also 
regulated by other factors such as the mammalian target of rapamycin complex 1 
(mTORC1) (113). The total and phosphorylated mTOR1 protein levels in the liver 
were quantified and the phosphorylated to total mTOR1 ratio which was 
indicative of mTOR1 activation was calculated (Fig. 3.13 A). The knockout 
groups demonstrated an increase in mTOR1 activation irrespective of Aroclor 
1260 exposure. The phosphorylated to total AMP-activated protein kinase α 
(AMPKα) protein levels were also quantified to assess AMPKα activation (Fig. 
109 
 
3.13 B). Aroclor 1260 exposure activated AMPKα in the WT and PXR knockout 










Figure 3.11. Effects of Aroclor 1260, CAR and PXR on hepatic expression of 
lipogenic and lipolytic genes. 
Real-time PCR experiments showed the changes in hepatic mRNA 
expressions caused by Aroclor 1260 exposure alone and/ or by ablating CAR or 
PXR for (A) FAS, (B) SCD1, (C) CD36, (D) FABP1 and (E) PNPLA2. Values are 
mean ± SEM, p <0.05, * - ∆ due to Aroclor 1260 exposure, # - ∆ due to knocking 
















Figure 3.12. Effects of Aroclor 1260, CAR and PXR on hepatic SREBP-1c 
expression and protein levels. 
 (A) Schematic diagram depicting CAR and PXR regulation on SREBP 
through Insig. The diagram was adapted from Hellard et al., Molecular 
Psychiatry, 14, 2009. Real-time PCR experiments showed the changes in 
hepatic mRNA expressions caused by Aroclor 1260 exposure alone and/or by 
ablating CAR or PXR for (B) SREBP-1c, (C) Insig-1 and (D) Insig-2. (E & F) 
Immunoblots for precursor and cleaved SREBP1 were performed, n=5. Active 
SREBP1 protein levels were quantified. Values are mean ± SEM, p <0.05, * - ∆ 



















Figure 3.13. Effects of Aroclor 1260, CAR and PXR on mTOR1 and AMPKα 
protein levels. 
(A) Immunoblots for mTOR1 and phosphorylated mTOR1 were performed. 
The phosphorylated to total mTOR1 ratio was quantified. (B) Immunoblots for 
AMPKα and phosphorylated AMPKα were performed. The phosphorylated to 
total AMPKα ratio was quantified. Values are mean ± SEM, p <0.05, * - ∆ due to 


















Effects of CAR/PXR on peroxisome proliferator-activated receptor alpha 
target genes 
Peroxisome proliferator-activated receptor alpha (PPARα) drives the 
transcription of genes involved in breaking down fatty acids such as carnitine 
palmitoyl transferase (CPTs) and Cyp4a10. Hepatic expression of PPARα as well 
as its target genes, CPT1A and Cyp4a10 was measured. The PPARα mRNA 
levels were higher in the Aroclor 1260-exposed mice compared to the unexposed 
mice in the WT and PXR-/- groups (Fig. 3.14 A). Although unexposed CAR-/- mice 
had increased PPARα mRNA levels vs. unexposed WT mice, Aroclor 1260 had 
no effect on PPARα expression in CAR-/- mice. In contrast, CPT1A was induced 
with Aroclor 1260 in all three groups irrespective of CAR/PXR ablation (Fig. 3.14 
B). Additionally, the Aroclor 1260-exposed PXR-/- mice showed the highest 
induction, and there was a significant interaction between PXR ablation and 
Aroclor 1260 exposure which was consistent with PPARα induction. Furthermore, 
Aroclor 1260 induced Cyp4a10 only in CAR-/- mice (Fig. 3.14 C). Also, PXR 












Figure 3.14. Effects of Aroclor 1260 exposure and CAR/PXR ablation on 
hepatic PPARα expression and its target genes. 
Real-time PCR experiments showed the changes in hepatic mRNA 
expressions caused by Aroclor 1260 exposure alone or by ablating CAR or PXR 
as well for (A) PPARα, (B) CPT1A and (C) Cyp4a10. Values are mean ± SEM, p 




















CAR and PXR target gene induction 
CAR hepatic mRNA levels were measured and as anticipated, there was 
no CAR mRNA in the CAR-/- mice. Aroclor 1260 exposure increased CAR mRNA 
expression (~2-fold) in WT mice (Fig. 3.15 A).  PXR ablation also increased CAR 
mRNA expression by ~10-fold as compared to WT groups. There was also a 
significant interaction between PXR ablation and Aroclor 1260 exposure in CAR 
induction. The mRNA levels of Cyp2b10, a CAR target gene, were significantly 
up-regulated in Aroclor 1260-exposed mice in the WT and PXR-/- groups (Fig. 
3.15 B). Moreover, the basal mRNA levels of Cyp2b10 were higher in the 
knockout groups, indicating a compensatory mechanism was driving CAR target 
gene expression in the absence of CAR. Notably, Aroclor 1260 did not induce 
Cyp2b10 in the CAR-/- group. 
Hepatic expression of PXR was also evaluated, and as expected, there 
was no PXR mRNA in the PXR-/- mice (Fig. 3.15 C). Aroclor 1260 did not induce 
PXR mRNA expression in the WT mice. In contrast Aroclor 1260 exposure did 
increase PXR expression (~17-fold) in the CAR-/- mice. Hepatic Cyp3a11 (PXR 
target gene) mRNA levels were up-regulated with Aroclor 1260 exposure in the 
CAR-/- group but not in the WT group (Fig. 3.15 D). Akin to Cyp2b10 expression, 
the Cyp3a11 basal expression levels were higher in the knockout groups. 
However, Aroclor 1260 did not induce Cyp3a1 in the PXR-/- group. Besides 
Cyp3a11, the hepatic expression of Ugt1a1, a predominant PXR target gene 
which also happens to be a CAR target gene, was measured (Fig. 3.15 E). 
Aroclor 1260 induced Ugt1a1 in the WT and CAR-/- groups. Interestingly, Ugt1a1 
120 
 
basal expression levels were higher only in the in the PXR-/- group but not in the 
CAR-/- group.  
Apart from CAR and PXR targets, the hepatic expression of Cyp1a2, an 
aryl hydrocarbon receptor (AhR) target gene was also measured (Fig. 3.15 F). 
There were no significant differences in the Cyp1a2 mRNA levels between the 
groups indicating that the AhR was not activated by Aroclor 1260 at the dose 

























Figure 3.15. Aroclor 1260 exposure altered hepatic expression of CAR and 
PXR target genes. 
Real-time PCR experiments showed the changes in hepatic mRNA 
expressions for (A), CAR, (B) Cyp2b10 (CAR target gene), (C) PXR, (D) 
Cyp3a11 (PXR target gene), (E) Ugt1a1 (PXR/CAR target gene)and (F) Cyp1a2 
(AhR target gene).  Values are mean ± SEM, p <0.05, * - ∆ due to Aroclor 1260 





















Aroclor 1260 was one of the first PCB mixtures manufactured and was 
later replaced by PCB mixtures with lower chlorine content. Although constituting 
only 11% of PCB mixtures manufactured, Aroclor 1260 was selected for this 
study based on its similarity to human PCB bioaccumulation patterns. The PCB 
congener composition in Aroclor 1260 consists of high molecular weight PCBs 
such as 5-, 6-, and 7-chlorinated congeners that are either not or very poorly 
metabolized so these congeners bio-accumulate in human and other biota. Most 
PCB studies in the past literature focused on occupational acute exposures that 
were associated with cancer-related endpoints and AhR activation. More 
recently, epidemiologic studies have revealed that PCB-exposed human cohorts 
showed signs of cardiovascular disorders, obesity, diabetes/insulin resistance 
and elevated liver enzymes (46, 52, 114).  
Clearly, chronic exposures to PCBs appear to disrupt lipid and glucose 
homeostasis and consequently lead to increased symptoms of diabetes and the 
metabolic syndrome in the exposed subjects (34, 52). Mechanistically, PCB 
action is thought to be mediated by the AhR and CAR. However, PCBs have also 
been shown to interact with endocrine and thyroid receptors as well as additional 
hepatic nuclear receptors including the PXR (97-99). Albeit being xenobiotic 
receptors, CAR and PXR are also involved in energy metabolism by acting 
directly or indirectly on enzymes involved in lipid and glucose metabolism (60-
62). We previously demonstrated that Aroclor 1260 induced liver injury in 
conjunction with HFD feeding. We also demonstrated that Aroclor 1260 activated 
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CAR and PXR in C57Bl/6 mice at 20 mg/kg exposure. The current study aimed 
at examining the role of CAR and PXR in Aroclor 1260-induced liver injury by 
using diet-induced obese CAR and PXR knockout mice.  
The findings from the study demonstrated that PXR was important in 
maintaining lower fat mass and liver weight because ablating this receptor 
resulted in increased adiposity/liver weight (Fig. 3.1). CAR ablation did not 
appear to interfere with adiposity. In fact, Aroclor 1260 exposure decreased 
bodyweight gain in CAR knockout mice, which may be due to increased physical 
activity and less food consumption displayed by this group. Interestingly, PXR 
was also over-expressed in this group. Presence of CAR and PXR also appeared 
crucial in maintaining energy homeostasis because ablating these receptors 
decreased the RER relative to WT mice, indicating only a lipid-metabolism state 
(Fig. 3.3). However, activation of either receptor by Aroclor 1260 restored the 
RER to a level similar to WT groups.  
When inflammation was examined, CAR and PXR ablation did not 
improve steatohepatitis induced by Aroclor 1260. Both CAR and PXR knockout 
mice showed signs of hepatic inflammation on high fat diet feeding alone, as 
evident by the TNFα and IL-6 basal expression levels (Fig. 3.6). These results 
suggested that both CAR and PXR play an inhibitory role in inflammation and 
activating these receptors by Aroclor 1260 is a protective mechanism in 
attenuating Aroclor 1260-induced toxicity. The role of PXR in inflammation is well 
documented relative to CAR (115). It is well known that exposure to xenobiotic 
chemicals such as rifampicin compromises the immune function and recent 
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studies have investigated the molecular mechanisms involved between PXR 
activation and inflammation. Zhou et al demonstrated that the interaction 
between PXR and nuclear factor kappa B (NF-κB) appeared to be reciprocal with 
both transcription factors mutually inhibiting each other (116). Enhanced 
expression of NF-κB target genes including TNFα, IL-2 and IL-6 was observed in 
the small bowel and liver of PXR knockout mice which was consistent with 
observations in the current study. Hu et al also showed increased hepatic 
expression of inflammatory cytokines in PXR knockout mice and demonstrated 
that liganded PXR was SUMOylated in hepatocytes in response to TNFα (117). 
Intriguingly; the SUMOylated PXR protein suppressed NF-κB target gene 
expression but had no effect on PXR target gene expression such as CYP3A4. 
The relationship between CAR and the inflammatory process is poorly 
understood, although some observations have implied its basal repression 
activity on NF-κB signaling (115). In the present study, it should be noted that 
even though Aroclor 1260 activated CAR/PXR in WT mice, their activation was 
not sufficient to protect the mice from hepatic and systemic inflammation, 
implying that Aroclor 1260 may affect liver injury by mechanisms other than the 
classically-defined receptor mechanisms.   
Cell culture studies indicated that activators of CAR and PXR repress 
hepatic gluconeogenic enzymes and therefore, CAR/PXR modulation of glucose 
metabolism possibly resulted in lowered blood glucose levels (71, 75). CAR and 
PXR inhibit gluconeogenic gene transcription, including PEPCK-1 and G6Pase, 
by directly binding to the transcription factor, forkhead boxO1 (FOXO1) and 
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preventing its transcriptional activity (74). CAR can also interfere with 
gluconeogenic gene expression by competing with the hepatocyte nuclear factor 
4 alpha (HNF4α) for binding at the PEPCK-1 promoter region. Also, CAR and 
PXR target the common co-activator utilized by numerous transcription factors, 
peroxisome proliferator-activated receptor gamma coactivator 1 alpha (PGC1α), 
resulting in the ‘squelching’ of PGC1α (118, 119). 
In the current study, hepatic expression of PEPCK-1 was enhanced in 
both CAR and PXR knockout mice (Fig. 3.9), implicating the loss of CAR- and 
PXR-inhibitory effect on PEPCK-1 transcription. PEPCK-1 was also induced with 
Aroclor 1260 exposure in the knockout mice, noticeably in PXR-/- mice, 
suggesting that PCB exposure increased gluconeogenic gene expression in 
absence of either CAR or PXR. Although fasting blood glucose levels were 
unchanged, all Aroclor 1260-exposed groups showed decreased serum insulin 
and HOMA-IR levels (Fig. 3.8). This observation is consistent with findings from 
our previous studies, associating compromised insulin secretion with PCB 
exposure, independent of CAR and/or PXR presence and activation. Thus the 
PXR knockout mice exposed to Aroclor 1260 showed increased AUC in a 
glucose tolerance test, potentially due to increased gluconeogenesis and 
decreased insulin synthesis required for glucose uptake. 
Another compelling observation in this study was the decreased 
leptin:adiponectin ratio in CAR and PXR knockout mice (Fig. 3.10). Circulating 
leptin:adiponectin ratio is considered a potential surrogate biomarker for obesity-
related conditions with higher leptin levels being observed consistently with 
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metabolic syndrome and diabetes/insulin resistance (120). In this study, serum 
adiponectin levels were higher in the knockout mice whereas leptin levels were 
not altered between the groups. Nonetheless, PXR knockout mice did not show 
any improvement in diet-induced obesity, despite the favorable leptin:adiponectin 
ratio while the CAR knockout mice displayed reduced adipocyte size.  
Aroclor 1260 exposure resulted in decreased FAS expression in WT mice 
(Fig. 3.11). However, the PXR knockout mice showed increased FAS basal 
levels indicating that activated PXR repress FAS transcription. Likewise, SCD1 
expression was decreased with Aroclor 1260 exposure; however its basal levels 
were increased only in CAR knockout mice suggesting that CAR could be a 
transcriptional repressor of SCD1. This supports other studies documenting 
decreased hepatic expression of lipogenic genes such as FAS and SCD1 during 
CAR activation (71, 72). Moreover, CAR suppression of LXRα transcriptional 
activity has also been reported, which could then cause downregulation of 
lipogenic gene expression (121). Additionally, Aroclor 1260 did not induce FAS or 
SCD1 in CAR knockout mice, therefore, this PCB mixture may not be a direct 
LXRα activator. In contrast, SREBP-1c was significantly induced only in PXR 
knockout mice exposed to Aroclor 1260, suggesting an interaction between PCB 
exposure and PXR ablation. However, simply measuring SREBP-1c expression 
alone may not be sufficient to determine the CAR/PXR effects on lipogenesis 
since both CAR and PXR also affect SREBP-1c activity through the anti-lipogenic 
gene, Insig (73). Therefore, it was more appropriate to measure active SREBP-
1c levels in the liver.  
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Contrary to our hypothesis, there was no reduction in active SREBP1 
protein levels with Aroclor 1260 exposure (Fig. 3.12). Rather, the Aroclor 1260 
exposed groups in the WT and CAR knockout mice had higher cleaved SREBP1 
protein levels than the unexposed group. Additionally, since the exposed groups 
did not show an increase in hepatic Insig-2 expression either, it appeared that 
CAR/PXR activation and ablation did not modulate hepatic gene expression 
through the Insig2-SCAB-SREBP1 pathway. Notably, hepatic Insig-1 expression 
was decreased in the Aroclor 1260 exposed groups. Insig-1 regulates the SCAB-
SREBP2 complex and its expression is regulated in part by nuclear SREBP 
levels and sterol deprivation (122). Furthermore, although it has been reported 
that CAR and PXR regulate lipogenesis by inducing Insig-1, the SREBP1 
retention in the endoplasmic reticulum has also been reported to be via Insig-2 
binding (123). However, Insig-2 expression did not differ among the groups. 
CAR and PXR ablation appeared to activate the mTOR1 complex pathway 
and Aroclor 1260 exposure appeared to activate AMPKα (Fig. 3.13). These are 
intriguing observations because mTOR and AMPK are considered as ‘energy 
sensors’ that regulate carbohydrate and lipid metabolism, thereby maintaining 
energy homeostasis at the cell and whole body level (124, 125). mTOR activation 
occurs during high nutrient availability or ‘fed’ state and usually favors anabolic, 
ATP-consuming processes that facilitate storage of nutrients such as lipogenesis 
and protein synthesis. Regulation of lipogenic SREBP1 by mTOR1 occurs at 
multiple levels (126). It has been demonstrated that high insulin levels can 
activate the mTOR1 complex through the Akt phosphorylation pathway (127). 
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Phosphorylated mTOR can phosphorylate the phosphatidic acid phosphatase 
Lipin-1, a transcriptional coactivator (113). Nuclear localized, dephosphorylated 
Lipin-1 inhibits SREBP1 nuclear localization and subsequently SREBP1 
transcriptional activity. Hence mTOR1 activation eventually leads to increased 
SREBP1 nuclear localization and activity. In this study, mTOR1 activation in the 
knockout groups possibly resulted in observable inductions of lipogenic gene 
expression. Interestingly, the WT mice exposed to Aroclor 1260 showed lower 
FAS and SCD1 expression which corroborated with lower phosphorylated 
mTOR1 levels. Moreover, the Aroclor 1260-exposed mice had lower insulin 
levels and this may have led to decreased phosphorylated mTOR1 levels 
compared to the unexposed mice in the WT group. However, this effect was lost 
with CAR and PXR ablation and the mechanisms related to this observation need 
to be investigated further. 
In contrast to mTOR1, AMPKα activation occurs during low nutrient 
availability or ‘fasted’ state and favors catabolic processes such as glycolysis 
(128). Besides, downstream AMPK signaling also inhibits anabolic processes 
that consume ATP. The mechanism involving AMPKα activation by Aroclor 1260 
exposure in the current study is unclear. However, AMPKα activation could be 
the reason for the increase in RER in the Aroclor 1260 exposed, PXR knockout 
mice. The same explanation could not be applied to the CAR knockout group 
because CAR ablation appeared to activate AMPKα irrespective of Aroclor 1260 
exposure. Also, it has been reported that metformin, an AMPK activator, inhibits 
CAR nuclear translocation and activation, indicating a complex relationship 
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between CAR and AMPK (129). Therefore more studies are necessitated with 
regard to PCB exposure and the mTOR and AMPK activation pathway. 
Aroclor 1260 induced CD36, a shared target gene of PXR, AhR and LXRα 
in WT mice (Fig. 3.11). It is known that PXR activators such as rifampicin can 
promote steatosis independent of the SREBP1 pathway by up-regulating hepatic 
CD36 (130). Interestingly, ablating PXR increased CD36 basal expression, 
implying that there may be some compensatory mechanisms affecting CD36 
expression in the absence of PXR. Furthermore, CD36 was also induced in the 
absence of PXR, indicating that Aroclor 1260 had other targets related to CD36 
induction and not restricted to PXR activation. Apart from lipogenic genes, the 
lipolytic gene PNPLA2 (adipose triglyceride lipase) was also evaluated. PNPLA2 
is expressed primarily in the adipose tissue as well as in the liver (131); it is 
involved in breaking down triglycerides to free fatty acids and one of its 
transcriptional mediators is FOXO1 which is in turn controlled by many factors 
including sirtuins (SIRT1) and insulin (132, 133). Being a FOX01 target gene, we 
assumed that hepatic PNPLA2 expression pattern in our study would be similar 
to that of PEPCK-1. Aroclor 1260 induced PNPLA2 in CAR knockout mice, 
similar to PEPCK-1. However in PXR knockout mice, the basal levels of hepatic 
PNPLA2 were increased and Aroclor 1260 induction was not observed, 
suggesting that PXR rather than CAR may be dominant in the sequestration of 
FOXO1 under basal conditions. Moreover, PEPCK-1 basal levels were also 
higher in PXR knockout mice when compared to CAR knockout mice.   
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Another distinct finding in this study was the regulation of PPARα target 
genes by CAR/PXR and Aroclor 1260 exposure (Fig. 3.14). Aroclor 1260 by itself 
increased PPARα expression in WT and PXR knockout mice but not in CAR 
knockout mice, suggesting that Aroclor 1260 exposure induced PPARα but 
activated PXR negatively regulates this induction. Interestingly, Aroclor 1260 
induced CPT1A, a PPARα target gene and rate limiting enzyme of mitochondrial 
fatty acid β-oxidation, in all three groups, and this was highest in the PXR 
knockout mice. Studies have shown the repression of CPT1A and other β-
oxidation related genes with PXR and CAR activation and their enhanced 
expression in knockout models (72, 77, 134). Apart from PPARα, CPT1A 
transcription is also mediated by the forkhead box protein A2 (FOXA2 ) and 
HNF4α (135, 136). PXR is a known inhibitor of FOXA2, and hence its ablation 
increased FOXA2 basal expression and inducibility by Aroclor 1260 (105). 
FOXA2 activity is also positively regulated by low levels of insulin which was 
displayed by all the Aroclor 1260-exposed groups (137). Another plausible 
mechanism for increased CPT1A expression in the knockout mice could be the 
increased availability of the peroxisome proliferator-activated receptor gamma 
coactivator 1-alpha (PCG1α) for HNF4α transcriptional activity. Cyp4a10, another 
PPARα target and enzyme involved in peroxisomal fatty acid oxidation, was 
induced with Aroclor 1260 exposure in CAR knockout mice. This finding is 
consistent with studies by Ueda et al, demonstrating that CAR is a negative 
regulator of Cyp4a10 expression and hence knocking out CAR enhanced 
Cyp4a10 induction by Aroclor 1260 (134). 
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Overall, our studies strongly indicated that CAR and PXR played a role in 
energy metabolism and validated previous findings that demonstrated xenobiotic 
receptor activation acts as an important factor in fatty liver disease and the 
metabolic syndrome (Fig. 3.16). In the current model, CAR and PXR activation 
appear to protect rather than augment Aroclor 1260-induced liver injury evident 
with worsened inflammation in CAR and PXR knockout mice. Moreover, the 
concept that CAR is an anti-obesity receptor and PXR is an obesity-promoting 
receptor may not reflect the complexity of Aroclor 1260 or environmental 
contaminant interaction with these transcription factors. It appears that both 
receptors are required for normal physiology and function and that they both 
portray similar if not identical outcomes on activation. Furthermore, our studies 
are consistent with previous observations on the effects of CAR and PXR in 
glucose and lipid metabolism. In contrast to the previous studies that employed 
model CAR and PXR ligands, this study used an environmental pollutant with 
multiple potential targets, which may also influence the end results of the study. 
These studies used knock out models to evaluate the distinct effects of these 
nuclear receptors in energy metabolism but it appears that Aroclor 1260 
exposure also causes other effects such as compromised insulin levels. In 
conclusion, nuclear receptors CAR and PXR are not merely detoxification 
receptors but they also have an important role in inflammation and endobiotic 
metabolism as well; both CAR and PXR play an important protective role in liver 






Figure 3. 16. Effects of CAR and PXR on hepatic energy metabolism. 
A schematic diagram depicting the potential therapeutic role of CAR and PXR 
activation in the metabolic syndrome. Figure adapted from Gao, et al., Trends 











HUMAN RECEPTOR ACTIVATION BY AROCLOR 1260 AND INDIVIDUAL 
PCB CONGENERS 
INTRODUCTION 
NAFLD and NASH were traditionally associated with the inappropriate 
over- or under-activation of nuclear receptors involved in endobiotic metabolism. 
These receptors include the LXR, farnesoid-X-receptor (FXR) and PPARs which 
regulate cholesterol, bile acid and lipid metabolism respectively (58, 59). Recent 
studies have implicated the role of hepatic receptors involved in xenobiotic 
detoxification, including PXR, CAR and the AhR in NAFLD/NASH. Although 
these receptors were initially thought to be involved only with detoxification and 
xenobiotic metabolism, over-activation or antagonism of these receptors may 
lead to metabolic disease states such as steatosis and obesity (60-62). 
Historically, PCB toxicity has been linked to cancer, endocrine disruption 
and impaired cognitive development, but recent studies have shown that chronic 
exposure to these environmental pollutants can result in metabolic disorders 
associated with NAFLD, including obesity, insulin resistance/diabetes and the 
metabolic syndrome (41, 102). Additionally, rodent studies have correlated PCB 
exposures with NAFLD, obesity and the metabolic syndrome suggesting the 
involvement of distinct nuclear receptors in PCB-mediated toxicity (48). It 
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remains unclear if the liver disease caused by PCB exposure is due to the direct 
involvement of receptors that regulate endobiotic metabolism such as LXR and 
FXR or if the disease process is linked to the activation/inhibition of xenobiotic 
receptors such as PXR and CAR.  
We hypothesized that PCBs may exert some of their toxic effects, such as 
NAFLD, by either interacting directly with the endobiotic nuclear receptors (LXR, 
FXR, PPARs) or through interaction with xenobiotic receptors that cross-talk with 
endobiotic receptors to otherwise modify their respective interactions with DNA 
response elements. Moreover, the interaction between Aroclor 1260 and these 
receptors that are implicated in NAFLD have never been tested. The purpose of 
this study is to evaluate the receptor agonism/antagonism by the PCB mixture, 
Aroclor 1260, and selected PCB congeners that are highly represented in this 
mixture. For the purpose of the studies, we collaborated with Dr. CJ Omiecinski 
from Penn State University to study PCB activation of the human CAR variants 
using COS-1 cells.  
The study demonstrated selective activation by Aroclor 1260 and selected 
PCB congeners on human AhR, PXR and CAR, and inhibition of PPARα. We 
postulate that hepatic transcription factor activation is part of the mode of action 







MATERIALS AND METHODS 
Materials 
Aroclor 1260 was purchased from AccuStandard (New Haven, CN, USA) 
and PCB congeners were obtained from Ultra Scientific (North Kingstown, RI, 
USA). T0901317 (N-(2,2,2-trifluoroethyl)-N-[4-[2,2,2-trifluoro-1-hydroxy-1-
(trifluoromethyl)ethyl]phenyl]-benzenesulfonamide), GW3965 (2-(3-(3-((2-chloro-
3-(trifluoromethyl)benzyl)(2,2-diphenylethyl)amino)propoxy)phenyl) acetic acid 
hydrochloride), GW4064 (3-[2-[2-chloro-4-[[3-(2,6-dichlorophenyl)-5-(1-
methylethyl)-4-isoxazolyl]methoxy]phenyl]ethenyl] benzoic acid) and pioglitazone 
were obtained from Tocris Bioscience (Bristol, UK). Dimethyl sulfoxide (DMSO) 
was acquired from Fisher BioReagents (Thermo Fisher Scientific, Pittsburg, PA, 
USA) while 6-(4-chlorophenyl)imidazo[2,1-b][1,3]thiazole-5-carbaldehyde-O-(3,4-
dichlorobenzyl)oxime (CITCO), rifampicin (RIF), benz[a]anthracene (BA) and 3-
(4, 5-Dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) were from 
Sigma Aldrich (St. Louis, MO, USA). Restriction endonucleases and T4 DNA 
ligase were purchased from New England BioLabs (Ipswich, MA). Lipofectamine 
and Opti-MEM were obtained from Life Technologies Inc (Carlsbad, CA, USA). 
Oligonucleotides were purchased from Integrated DNA Technologies (Coralville, 
IA, USA). 
Plasmid construction 
The reporter plasmids for human (h) PXR (pGL3-DR4-Luc), hFXR (pGL3-
IR1-Luc) and hPPARα (pGL3-DR1-Luc) were constructed by using two copies of 
a direct repeat 4 (DR4), an inverted repeat 1 (IR1) and a direct repeat 1(DR1) 
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response element (RE) respectively. The top strand oligonucleotide was  5’ 
AGAGTTCATGAGAGTTCATGAGAGTTCATGAGAGTTCATG 3’ for pGL3-DR4-
Luc, 5’ AGAGGTCATTGACCTTTAGAGGTCATTGACCTTT 3’ for pGL3-IR1-Luc 
and 5’ AACTAGGTCAAAGGTCAAACTAGGTCAAAGGTCAAA 3’ for pGL3-DR1-
Luc. Both the bottom complementary strands had Kpn1 and Xho1 overhangs at 
the 5’ and 3’ positions respectively. The oligonucleotides were annealed and 
inserted into Xho1 and Kpn1 restriction sites in the polycloning region of a 
modified version of pGL3 promoter vector (Promega, Madison, WI, USA). 
Reporter plasmid for AhR (pXRE-SV40-Luc) was synthesized using the 
oligonucleotide 5’ TCAGGCATGTTGCGTGCATCCCTGAGGCCAGCC 3’ 
inserted into the EcoR1 site of a modified version of pGL3 promoter vector. 
Expression vectors pSG5-hLXRα, pSG5-hPXR and pSG5-hFXR and reporter 
plasmid pTK-LXRE-Luc were a generous gift from John Y. Chiang (Department 
of Integrative Medical Sciences, Northeast Ohio Medical University). Expression 
vectors pCMV6-hPPARα, pCMV6-hPPARγ and pCMV6-hCAR (CAR2) were 
purchased from Origene (Rockville, MD, USA). The vectors, pTracer CMV2-
hCAR1, pTracer CMV2-hCAR2, pcDNA 3.1-RXRα, and pGL3- basic/TK 
CYP2B6-dervied XREM/PBREM were described previously (138). pTracer 
CMV2-CAR3 was also reported previously (139). pRL-CMV, the expression 
plasmid encoding Renilla luciferase, was purchased from Promega (Madison, 
WI, USA) and used in the Dual-Glo (Promega) assay system according to the 
manufacturer’s protocol to normalize for transfection efficiencies in cultured cells. 
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Prior to transfection, plasmids were prepared using the Qiagen Plasmid Plus Midi 
Kit (Qiagen, Valencia, CA, USA). 
Cell culture 
HepG2 cells: The human hepatoma-derived cell line (HepG2) was 
obtained from the American Type Culture Collection (ATCC, Manassas, MD, 
USA). Cells were grown in Dulbecco’s modified Eagle’s medium (DMEM, 
HyClone Laboratories Inc, Thermofisher, Waltham, MA, USA) supplemented with 
10% fetal bovine serum (FBS) and 1% antimycotic/antibiotic solution (Mediatech, 
Manassas, VA, USA). The cells were incubated in a 5% carbon dioxide 
atmosphere and 95% humidity at 37 °C and subcultured every 2 days. 
 COS-1 cells: COS-1 cells (Simian virus-40–transformed African green 
monkey kidney cells) were obtained from the ATCC and maintained in DMEM 
plus GlutaMAX-I with 10% FBS,10mM 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES), 1mM sodium pyruvate, 13 non-essential 
amino acids, and 1% penicillin/streptomycin. COS-1 cells were cultured at 37 °C 
in a humidified atmosphere containing 5% carbon dioxide. All cell culture 
reagents were purchased from Life Technologies (Grand Island, NY, USA).  
Cell viability assay 
HepG2 cells were seeded in 96-well tissue culture plates at a seeding 
density of 10,000 cells per well. Cells were treated with graded concentrations of 
Aroclor 1260 made up as 500X stocks in DMSO. Controls received DMSO only. 
After 24 h incubation, MTT (0.2 mg/ml) was added to the cells and incubated for 
3-4 h. The media were removed from the plates by aspiration and formazan dye 
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was liberated by adding 50 µL DMSO. MTT, a yellow tetrazole, was reduced to 
an insoluble product formazan by mitochondrial reductases, indicative of cell 
viability. Presence of formazan, a purple precipitate, was determined 
spectrophotometrically at 540 nm using a Bio-Tek Synergy HT multi-mode micro 
plate reader (Winooski, VT, USA).  
Transfection 
HepG2 cells were plated in Thermo Scientific Nunc 24-well plates and 
transfected at 40-60% confluence. Unless otherwise specified, the transfection 
mix per well contained 150 ng β-galactosidase expression plasmid (pCMV-β, 
Stratagene, CA) as a transfection control, 50 ng receptor expression plasmid and 
150 ng reporter plasmid. All cells were co-transfected by lipofection using 
Lipofectamine reagent according to the manufacturer’s instructions and Opti-
MEM (reduced serum medium) as the transfecting medium. After 4 hour 
incubation, the medium was changed to DMEM supplemented with 10% FBS 
and 1% antimycotic/antibiotic solution and cells were allowed to recover 
overnight. DMEM supplemented with charcoal/dextran treated FBS (HyClone 
Laboratories Inc, Thermofisher, Waltham, MA, USA) was used for PPAR 
activation assays. Compounds of interest were then added to the cells (n=4) and 
cells were incubated for 24 h. DMSO was used as a carrier for all compounds 
(final concentration <0.5%). For COS-1 cells, all media components remained the 
same except that FBS was replaced with 10% dextran/charcoal-treated FBS 
(HyClone, Logan, UT, USA). The details of the luciferase reporter assays were 
described previously (138-140). Briefly, approximately 1 h prior to transfection, 
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cells were trypsinized and plated onto 48-well plates (~50,000 cells per well). For 
determination of transcriptional activity of the hCAR constructs, cells were 
transfected using Fugene 6 (Promega) according to the manufacturer’s 
recommendations with a co-transfection plasmid mix consisting of 10 ng pRL-
CMV (Renilla luciferase) for normalization, 25 ng pcDNA 3.1-RXRα, 100 ng of 
pGL3-basic/TK XREM/PBREM luciferase reporter plasmid, and 25 ng of pTracer 
vectors containing the various CMV2-CAR expression constructs. Each condition 
was performed in quadruplicate. Aroclor 1260 and each of the PCBs were 
evaluated at 10 µM. DMSO was used as a solvent control. CITCO, 5 µM, was 
used as a positive control. Androstanol (ANDR), a known inverse agonist of 
human CAR, was used as a control for CAR1.  
Reporter assay 
HepG2 cells: Cells were washed twice with Phosphate Buffered Saline 
(1X), harvested using 50 µL cell lysis buffer (Promega, Madison, WI, USA) and 
subjected to a single freeze-thaw event.  For β-galactosidase assays, cell 
extracts (5 µL), were incubated with chlorophenol red β-galactopyranoside 
(CPRG, Roche Diagnostics, Indianapolis, IN) at 37 °C for 30-60 minutes. The 
enzyme activity was determined spectrophotometrically at 595 nm using the Bio-
Tek Synergy HT multi-mode micro plate reader. Luciferase activity assays were 
performed on cell extracts (5 µL) using the Luciferase Assay System (Promega). 
Luminescence was measured using the Orion L micro plate luminometer 
(Berthold Detection Systems, Pforzheim, Germany) over a 10 second period. 
Receptor activation was measured by luciferase activity and results were 
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normalized to the amount of β-galactosidase expressed. COS-1 cells: Luciferase 
assays were performed using the Dual-Glo Reporter Assay System (Promega) 
and a Veritas Microplate Luminometer (Turner Biosystems, Sunnyvale, CA, 
USA). Firefly (Photinus pyralis) luminescence data values were recorded for 
each replicate and normalized luciferase activities were then calculated by 
dividing the raw luciferase values by the Renilla luciferase signals to correct for 
any differences in transfection efficiency among the assay wells. 
Validation of receptor activation in primary human hepatocytes 
Human hepatocytes were obtained from BioreclamationIVT (Baltimore, 
MD, USA).  Hepatocytes were thawed and plated in 12-well plates according to 
the supplier’s protocols and the compounds of interest were added. The cells 
were incubated for 24 h and RNA was extracted using RNA STAT-60 protocol 
(Tel-test, Austin, TX, USA). RNA purity and quantity were assessed with the 
Nanodrop (ND-1000, Thermo Scientific, Wilmington, DE, USA) using the ND-
1000 V3.8.1 software. cDNA was synthesized from total RNA using the 
QuantiTect Reverse Transcription Kit (Qiagen, Valencia, CA, USA). Polymerase 
chain reaction (PCR) was performed on the Applied Biosystems StepOne Plus 
Real-Time PCR Systems using the Taqman Universal PCR Master Mix (Life 
Technologies, Carlsbad, CA, USA). Each PCR mix (20 µL) contained: Taqman 
Universal PCR Master Mix (10 µL), 20X Gene Expression Assay Mix (1 µL), 
cDNA sample (2 µL) and nuclease-free water (7 µL). Primer sequences from 
Taqman Gene Expression Assays (Applied Biosystems, Foster City, CA, USA) 
were as follows: cytochrome P450s [CYP3A4 (Hs00604506_m1), CYP2B6 
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(Hs04183483_g1), CYP1A1 (Hs01054797_g1)], CD36 (Hs01567185_m1), fatty 
acid synthase (FAS) (Hs01005622_m1), carnitine palmitoyl transferase 1A 
(CPT1A), (Hs00912671_m1), small heterodimeric partner (SHP) 
(Hs00222677_m1) and glyceraldehyde-3-phosphate dehydrogenase (GAPDH). 
Cycle conditions were maintained according to the Applied Biosystems guide. 
The levels of mRNA were normalized relative to the amount of GAPDH mRNA, 
and expression levels in DMSO-exposed cells were set at 1%. Gene expression 
levels were calculated according to the 2-∆∆Ct method (92).  
Statistical analysis 
Statistical analyses were performed using GraphPad Prism version 5.01 
(San Diego, CA, USA). In general for all assays, data are expressed as means ± 
SEM. Quantitative data for two group comparisons were assessed using an 
unpaired t-test. Multiple group data were examined by one way analysis of 
variance followed by the Dunnett’s post hoc test to compare all groups to the 
control sample. Multiplicity adjusted p values are reported in the Results section. 
















Cell viability assay for Aroclor 1260 
MTT assays were performed to determine the optimal concentration for 
Aroclor 1260 that does not cause toxicity in HepG2 cell culture experiments. 
Cells were exposed to this PCB mixture at concentrations ranging from 1.25 - 
250 µg/mL. The optical density for formazan, representative of cell viability, was 
plotted against Aroclor 1260 concentrations. The toxicity threshold (concentration 
that caused 50% cell death) was determined to be 26.0 ± 3.7 µg/mL (Fig. 4.1). 
















Figure 4.1. Cell viability assay for Aroclor 1260. 
HepG2 cells were exposed to Aroclor 1260 at concentrations ranging from 
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Aroclor 1260 activation of the human aryl hydrocarbon receptor  
 Coplanar PCBs (PCBs 126 and 77) activate AhR in rodents and hence 
are classified as “dioxin-like” PCBs. Coplanar congeners comprise only ~1% of 
the total composition in Aroclor 1260. HepG2 cells, co-transfected with pXRE-
SV40-Luc, were exposed to various concentrations of Aroclor 1260 for 24 h and 
the normalized luciferase activity was measured. As anticipated, AhR was 
activated by its polycyclic aromatic hydrocarbon ligand BA (10 µM), and Aroclor 
1260 exposure resulted in a significant increase in luciferase activity (3.5-fold at 
20 µg/mL, p <0.0001) compared to DMSO-exposed cells (Fig. 4.2 A). However, 
this fold induction was relatively low when compared to that of BA. These results 
indicate that Aroclor 1260 has a weak AhR agonistic activity that is likely due to 
the presence of coplanar congeners at lower concentrations in the mixture. AhR 
activation by BA was assessed in the presence of increasing concentrations of 
Aroclor 1260 to evaluate for any potentiation or antagonism effects. Cells co-
exposed to BA and Aroclor 1260 showed no difference vs. BA-exposed cells only 
(Fig. 4.2 B).  
Next, we selected ten non-coplanar congeners that are more highly 
represented in Aroclor 1260 mixture (≥1%) as well as two coplanar congeners 
(PCBs 126 and 118) and tested the ability of these compounds to individually 
activate AhR at a concentration of 10 µM. Although PCB 126 (no ortho) 
constitutes ~0.002% of the total PCB composition in Aroclor 1260, it was 
selected for this study because it is a good AhR activator (141). PCB 118 (mono-
ortho) was chosen because it was one of the coplanar congeners with the 
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highest composition in Aroclor 1260 (0.48%). Among the selected congeners, 
coplanar PCB 126 and non-coplanar PCB 138 significantly induced luciferase 
activity (17-fold, p <0.0001 and 4-fold, p =0.0006 respectively), while coplanar 
PCB 118 did not induce luciferase activity (1.2-fold) compared to DMSO-exposed 
cells (Fig. 4.2 C). Thus it appeared that PCB 118 did not activate AhR at the 
concentration used, unlike PCB 126. Besides, AhR activation was not restricted 



















Figure 4.2. Aroclor 1260 activation of the human AhR. 
HepG2 cells were transiently transfected with the reporter plasmid pXRE-
SV40-Luc. Benz[a]anthracene (10 µM, BA) was used as a positive control. (A) 
Cells were exposed to Aroclor 1260 at 0, 5, 10, 15 and 20 µg/mL and luciferase 
induction was normalized and compared to DMSO-exposed cells (0 µg/mL 
Aroclor 1260). (B) Cells were exposed to 10 µM BA or BA plus Aroclor 1260 at 0, 
5, 10, 15 and 20 µg/mL. The luciferase induction was normalized to that of cells 
exposed only to DMSO solvent carrier (as in A, not shown). Luciferase activity in 
cells exposed to BA and Aroclor 1260 was compared to that of BA-exposed cells. 
(C) Cells were exposed to selected PCB congeners (10 µM) present in Aroclor 
1260 and the induction was compared to DMSO-exposed cells. Data were 
normalized to luciferase activity in cells exposed only to DMSO and are 
expressed as mean ± SEM, n=4, * p <0.05. Figure adapted from Wahlang et al., 











Aroclor 1260 activation of the human pregnane xenobiotic receptor  
Non-coplanar PCBs, including PCBs 153 and 196, have been predicted to 
activate the nuclear receptors PXR and CAR, and these PCBs are often referred 
to as “phenobarbital-like”. Apart from regulating xenobiotic metabolism, PXR 
activation is implicated in weight gain and obesity (60, 142). Moreover, since 
PXR and CAR do share similar ligands to an extent, it is therefore likely that 
Aroclor 1260, being largely composed of non-coplanar PCBs, will activate PXR. 
HepG2 cells, co-transfected with pSG5-hPXR and pGL3-DR4-Luc were 
exposed to various concentrations of Aroclor 1260 for 24 h. RIF (10 µM), a PXR 
ligand, was used as a positive control. RIF activated PXR-driven luciferase 
activity (2.6-fold, p <0.0001) whereas Aroclor 1260 activated the receptor in a 
concentration-dependent manner with a Km value of 8.75 µg/mL (Fig. 4.3 A). 
Cells exposed to Aroclor 1260 at 5 µg/mL showed no significant induction in 
luciferase activity as compared to cells exposed to DMSO only. However, the 
induction was significant at concentrations of 10 (1.9-fold, p =0.0024), 15 (2.1-
fold, p =0.0001) and 20 (2.7-fold, p <0.0001) µg/mL. When transfected cells were 
exposed to both RIF and Aroclor 1260 (5 µg/mL and above) simultaneously, 
there was a slightly higher induction (~18%) compared to RIF-exposed cells 
alone (Fig. 4.3 B) but this was not significant. These data suggest that Aroclor 
1260 activated the PXR reporter system at concentrations of 10 µg/mL and 
higher and that the mixture did not significantly potentiate or antagonize PXR 
activation by the receptor ligand, RIF. We then evaluated the ability of selected 
PCB congeners to activate PXR (Fig. 4.3 C). Of the congeners tested, non-
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coplanar PCBs that significantly increased luciferase activity at 10 µM included 
PCBs 149 (2.1-fold, p <0.0001), 138 (1.7-fold, p =0.0006), 187 (2.0-fold, p 
<0.0001), 174 (2.3-fold, p <0.0001), 151 (1.6-fold, p =0.0062), 183 (1.6-fold, p 
=0.0067) and 196 (1.6-fold, p =0.0036). Notably, these congeners in total 
represent more than 30% of the Aroclor 1260 mixture by mass. Interestingly, 
PCB 126, a well-known AhR ligand and a coplanar congener also activated 
human PXR (1.9-fold, p <0.0001), indicating that a PCB’s non-coplanar structure 


















Figure 4.3. Aroclor 1260 activation of the human PXR. 
HepG2 cells were transiently transfected with the expression plasmid 
pSG5-hPXR and reporter plasmid pGL3-DR4-Luc. Rifampicin (10 µM, RIF) was 
used as a positive control. (A) Cells were exposed to Aroclor 1260 at 0, 5, 10, 15 
and 20 µg/mL and luciferase induction was normalized and compared to DMSO-
exposed cells (0 µg/mL Aroclor 1260). (B) Cells were exposed to 10 µM RIF or 
RIF plus Aroclor 1260 at 0, 5, 10, 15 and 20 µg/mL. The luciferase induction was 
normalized to that of cells exposed only to DMSO solvent carrier (as in A, not 
shown). Luciferase activity in cells exposed to RIF and Aroclor 1260 was 
compared to that of RIF-exposed cells. (C) Cells were exposed to selected PCB 
congeners (10 µM) present in Aroclor 1260 and the induction was compared to 
DMSO-exposed cells. Data were normalized to luciferase activity in cells 
exposed only to DMSO and are expressed as mean ± SEM, n=4, * p <0.05. 












Aroclor 1260 activation of the human constitutive androstane receptor  
In these experiments, HepG2 cells were co-transfected with pCMV6-
hCAR (CAR2) and pGL3-DR4-Luc and the ability of Aroclor 1260 to transactivate 
CAR2 was evaluated. CAR 2 is a human splice variant of the CAR1 reference 
form of the receptor, but unlike the reference form, CAR2 is not constitutively 
active; rather, it is a ligand activated receptor (138). Although somewhat modest, 
the human CAR agonist CITCO and Aroclor 1260 (10 µg/mL) significantly 
activated CAR2 (2.8-fold, p <0.0001 and 1.6-fold, p =0.0240 respectively) (Fig. 
4.4 A). However, increasing the concentration of Aroclor 1260 did not lead to 
further CAR2 activation (1.1-fold at 15 µg/mL and 1.4-fold at 20 µg/mL 
respectively). Rather, this PCB mixture appeared to antagonize CAR2 activation 
by CITCO (Fig. 4.4 B). Aroclor 1260, at 20 µg/mL, significantly reduced the 
induction produced by CITCO by 51% (p =0.0314). These results suggested that 
Aroclor 1260 may bind to CAR2 and either activate CAR2 or inhibit CAR2 
activation by CITCO in a concentration-dependent manner. Interestingly, two of 
the selected congeners, PCBs 187 (p =0.0042) and 126 (p =0.0031), increased 
luciferase induction significantly at 10 µM concentration (Fig. 4.4 C), indicating 
that some of the PCB congeners in Aroclor 1260 may be CAR2 agonists. 
Given the apparent impact of these PCB congeners on human CAR, we 
designed a complimentary series of assays to further corroborate and better 
characterize these effects using the primate-derived cell line, COS-1. These 
results are presented in Figure 4.5. Due to the high constitutive activity of CAR1, 
any ligand interactions with the receptor tend to be masked. In these respects, it 
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is notable that PCB 174 significantly inhibited the constitutive activity of CAR1 (p 
<0.05), though not as remarkably as ANDR (p <0.001), a known CAR inverse 
agonist (Fig. 4.5 A). Although the level of activation of CAR2 did not reach the 
level of the CITCO positive control (5.4-fold, p <0.001), Aroclor 1260 as well as 
several other PCB congeners demonstrated significant CAR2 activation in the 
COS-1 cell assays (Fig. 4.5 B). Exhibiting a fold change of 2.4 (p <0.001), PCB 
126 elicited the greatest response - even greater than Aroclor 1260 (1.7-fold, p 
<0.05). Four additional congeners also activated CAR2: 180 (1.7-fold, p <0.05), 
149 (1.9-fold, p <0.01), 187 (2.0-fold, p <0.001) and 196 (1.8-fold, p <0.01). 
CAR3, another ligand activated human splice variant, which likely maintains a 
conserved ligand binding pocket with CAR1, was also tested and exhibited 
significant activation effects with Aroclor 1260 (7.6-fold, p <0.001) (Fig. 4.5 C). 
Several other PCB congeners also demonstrated significant CAR3 activation 
including PCB 187 (17.1-fold, p <0.001; comparable to CITCO at 18.5-fold, p 
<0.001), PCB 153 (6.0-fold, p <0.01), PCB 149 (10.6-fold, p <0.001), PCB 138 
(8.3-fold, p <0.001), PCB 151 (5.5-fold, p <0.01), and PCB183 (15.1-fold, p 











Figure 4.4. Aroclor 1260 activation of the human CAR2 transcript. 
HepG2 cells were transiently transfected with the expression plasmid 
pCMV6-hCAR (CAR2) and reporter plasmid pGL3-DR4-Luc. CITCO (10 µM) was 
used as a positive control. (A) Cells were exposed to Aroclor 1260 at 0, 5, 10, 15 
and 20 µg/mL and luciferase induction was normalized and compared to DMSO-
exposed cells (0 µg/mL Aroclor 1260). (B) Cells were exposed to 10 µM CITCO 
or CITCO plus Aroclor 1260 at 0, 5, 10, 15 and 20 µg/mL. The luciferase 
induction was normalized to that of cells exposed only to DMSO solvent carrier 
(as in A, not shown). Luciferase activity in cells exposed to CITCO and Aroclor 
1260 was compared to that of CITCO-exposed cells. (C) Cells were exposed to 
selected PCB congeners (10 µM) present in Aroclor 1260 and the induction was 
compared to DMSO-exposed cells. Data were normalized to luciferase activity in 
cells exposed only to DMSO and are expressed as mean ± SEM, n=4, * p <0.05. 















Figure 4.5. Aroclor 1260 activation of the human CAR variant transcripts in 
COS-1 cells. 
COS-1 cells were transiently transfected with expression plasmid 
pTracerCMV2 containing either (A) CAR1, (B) CAR2 or (C) CAR3 transcripts, 
together with the reporter plasmid, pGL3-2B6XREM/PBREM-TKLuc. Cells were 
exposed to selected PCB congeners (10 µM) present in Aroclor 1260 and the 
induction was compared to DMSO-exposed cells. CITCO (5 µM) was used as a 
positive control. ANDR (10 µM), a CAR inverse agonist, was used as a negative 
control for CAR1. Data were normalized to luciferase activity in cells exposed 
only to DMSO and are expressed as mean ± SEM, n=4, * p <0.05. Figure 















Effect of Aroclor 1260 on the human liver-X-receptor alpha  
The human LXRα is a subtype of LXR that is expressed in the liver and its 
under- or over-activation eventually leads to steatosis (143). We therefore 
hypothesized that Aroclor 1260 may activate LXRα and this activation may 
subsequently promote hepatic steatosis and NAFLD. HepG2 cells, co-transfected 
with pSG5-hLXRα and pTK-LXRE-Luc, were exposed to various concentrations 
of Aroclor 1260 for 24 h and the normalized luciferase activity measured. 
T0901317, a synthetic LXRα ligand was used as a positive control. Compared to 
the fold induction by T0901317 (100 nM), Aroclor 1260 did not activate LXRα nor 
antagonize LXRα activation by T0901317 at any concentration tested (Fig. 4.6 
A&B), thus indicating that this PCB mixture is neither an agonist nor antagonist of 




















Figure 4.6. Aroclor 1260 activation of the human LXRα. 
HepG2 cells were transiently transfected with the expression plasmid 
pSG5-hLXRα and reporter plasmid pTK-LXRE-Luc. T0901317 (100nM, T) was 
used as a positive control. (A) Cells were exposed to Aroclor 1260 at 0, 5, 10, 15 
and 20 µg/mL and luciferase induction was normalized and compared to DMSO-
exposed cells (0 µg/mL Aroclor 1260). (B) Cells were exposed to 100 nM T or T 
plus Aroclor 1260 at 0, 5, 10, 15 and 20 µg/mL. Luciferase activity in cells 
exposed to T and Aroclor 1260 was compared to that of T-exposed cells. Data 
were normalized to luciferase activity in cells exposed only to DMSO and are 
















Effect of Aroclor 1260 on the human farnesoid-X-receptor 
The ability of Aroclor 1260 to activate FXR, a key regulator of bile acid and 
energy metabolism was evaluated. HepG2 cells, co-transfected with pSG5-hFXR 
and pGL3-IR1-Luc were exposed to various concentrations of Aroclor 1260 for 
24 h. GW4064 (0.5 µM), a synthetic FXR agonist, was sed as a positive control. 
GW4064 activated FXR whereas Aroclor 1260 did not induce a response at any 
of the concentrations tested. In studies to test antagonism, all concentrations 
tested were without effect on the activation of human FXR (Fig. 4.7 A&B). Thus, 
























Figure 4.7. Aroclor 1260 activation of the human FXR. 
HepG2 cells were transiently transfected with the expression plasmid 
pSG5-hFXR and reporter plasmid pGL3-IR1-Luc. GW4064 (0.5 µM, GW) was 
used as a positive control. (A) Cells were exposed to Aroclor 1260 at 0, 5, 10, 15 
and 20 µg/mL and luciferase induction was normalized and compared to DMSO-
exposed cells (0 µg/mL Aroclor 1260). (B) Cells were exposed to 0.5 µM GW or 
GW plus Aroclor 1260 at 0, 5, 10, 15 and 20 µg/mL. Luciferase activity in cells 
exposed to GW and Aroclor 1260 was compared to that of GW-exposed cells. 
Data were normalized to luciferase activity in cells exposed only to DMSO and 
















Effect of Aroclor 1260 on the human peroxisome-proliferator activated 
receptors  
 PPARs are a group of nuclear receptors that mediate peroxisomal 
proliferation with subtype alpha (α) playing a distinct transcriptional role in lipid 
metabolism in the liver and the subtype gamma (γ) in the adipose tissue. It was 
therefore important to evaluate the effect of Aroclor 1260 on PPARs α and γ 
activation. HepG2 cells were co-transfected with pCMV6-hPPARα and pGL3-
DR1-Luc. Nafenopin was used as a positive control. Aroclor 1260 did not activate 
PPARα at any of the concentrations (Fig. 4.8. A). In studies to test antagonism, 
Aroclor 1260 at the highest concentration (20 µg/mL) significantly antagonized 
PPARα activation induced by nafenopin (27%, reduction, p =0.0222, Fig. 4.8. B). 
Possible antagonism of PPARα by individual PCB congeners also was tested at 
10 µM concentration (Fig. 4.8. C). However, none of the selected congeners 
reduced the induction by nafenopin significantly, suggesting that a combination of 
the congeners is required to produce a marked effect or that other congeners 
present in this mixture may contribute to this effect.  
For PPARγ activation, HepG2 cells were co-transfected with pCMV6-
hPPARγ and pGL3-DR1-Luc. Pioglitazone was used as a positive control. 
Aroclor 1260 did not activate PPARγ nor antagonize PPARγ activation by 








Figure 4.8. Aroclor 1260 activation of the human PPARα.  
HepG2 cells were transiently transfected with the expression plasmid 
pCMV6-hPPARα and reporter plasmid pGL3-DR1-Luc. Nafenopin (50 µM, N) 
was used as a positive control. (A) Cells were exposed to Aroclor 1260 at 0, 5, 
10, 15 and 20 µg/mL and luciferase induction was normalized and compared to 
DMSO-exposed cells (0 µg/mL Aroclor 1260). (B) Cells were exposed to 50 µM N 
or N plus Aroclor 1260 at 0, 5, 10, 15 and 20 µg/mL. The luciferase induction was 
normalized to that of cells exposed only to DMSO solvent carrier (as in A, not 
shown). (C) Cells were exposed to selected PCB congeners (10 µM) present in 
Aroclor 1260 and the induction was compared to DMSO-exposed cells.  
Luciferase activity in cells exposed to N and Aroclor 1260 was compared to that 
of N-exposed cells. Data were normalized to luciferase activity in cells exposed 
only to DMSO and are expressed as mean ± SEM, n=4, * p <0.05. Figure 



















Figure 4.9. Aroclor 1260 activation of the human PPARγ. 
HepG2 cells were transiently transfected with the expression plasmid 
pCMV6-h PPARγ and reporter plasmid pGL3-DR1-Luc. Pioglitazone (10 µM, P) 
was used as a positive control. (A) Cells were exposed to Aroclor 1260 at 0, 5, 
10, 15 and 20 µg/mL and luciferase induction was normalized and compared to 
DMSO-exposed cells (0 µg/mL Aroclor 1260). (B) Cells were exposed to 10 µM P 
or P plus Aroclor 1260 at 0, 5, 10, 15 and 20 µg/mL. Luciferase activity in cells 
exposed to P and Aroclor 1260 was compared to that of P-exposed cells. Data 
were normalized to luciferase activity in cells exposed only to DMSO and are 
















Aroclor 1260 exposure and gene expression in human hepatocytes  
To confirm our findings, we tested the effects of Aroclor 1260 exposure on 
target gene expression profiles in human hepatocytes. Primary hepatocytes were 
exposed to Aroclor 1260 at 5, 10, 15 and 20 µg/mL and gene expression was 
measured by RT-PCR. The mRNA expression of target genes namely CYP1A1, 
CD36, CYP3A4, CYP2B6, CPT1A, FAS and SHP were significantly induced by 
the respective receptor agonists in primary human hepatocytes (Fig. 4.10. A). 
Expression levels of CYP1A1, an AhR target gene were significantly 
increased when hepatocytes were exposed to Aroclor 1260 (15 µg/mL, p 
=0.0018, and 20 µg/mL, p =0.0066, vs. unexposed cells) (Fig. 4.10. B). Contrary 
to CYP1A1, CD36, another AhR target gene was not induced by Aroclor 1260 
exposure, suggesting that CD36 is not as inducible as CYP1A1 (Fig. 4.10. C). 
CD36 expression, however, is regulated by other transcription factors in addition 
to AhR (94). Furthermore, CYP3A4 (PXR target gene) mRNA expression was 
upregulated by Aroclor 1260 exposure at 15 µg/mL (p =0.0083) and 20 µg/mL (p 
=0.0303) (Fig. 4.10. D). Irrespective of the CAR2 antagonism observed in 
transfection assays, Aroclor 1260 induced CYP2B6 (CAR target gene) at 15 
µg/mL (p =0.0114) and 20 µg/mL (p =0.0036) (Fig. 4.10. E). Expression levels of 
other genes including FAS (LXR target gene), SHP (FXR target gene) and 
CPT1A (PPARα target gene) were not affected by Aroclor 1260 exposure (Fig. 
4.10. F, G&H respectively), thus confirming our results obtained from the HepG2 












Figure 4.10. Effects of Aroclor 1260 on target genes in primary hepatocytes. 
Primary human hepatocytes were exposed either to receptor ligands or 
different concentrations of Aroclor 1260. After a 24 hour incubation, RNA was 
isolated and RT-PCR was performed. (A) The mRNA levels of selected receptor 
target genes were upregulated by receptor ligands (positive control) namely BA 
(10 µM) for CYP1A1 and CD36, RIF (10 µM) for CYP3A4, CITCO (10 µM) for 
CYP2B6, T0901317 (100 nM) for FAS, nafenopin (50 µM) for CPT1A and 
GW4065 (0.5 µM) for SHP. Relative mRNA levels of target genes were 
measured in Aroclor 1260-exposed cells namely (B) CYP1A1, (C) CD36, (D) 
CYP3A4, (E) CYP2B6, (F) FAS, (G) SHP and (H) CPT1A. Figure adapted from 
















Our laboratory recently identified suspected NAFLD and toxicant-
associated steatohepatitis in NHANES participants with low-level environmental 
exposures to POPs, including 20 PCBs (18). Epidemiologic studies have shown 
a positive association between adipose tissue concentrations of PCBs and type 2 
diabetes (42, 144). High serum PCB levels were also associated with elevated 
serum triglycerides and cholesterol which are major risk factors for 
cardiovascular diseases (145). Exposure to PCB mixtures has also been 
associated with elevated liver enzymes in plasma and hepatomegaly (53). 
Clearly, chronic exposures to these chlorinated compounds appear to disrupt 
both lipid and glucose homeostasis and consequently lead to diabetes and 
associated metabolic disorders such as NAFLD. Therefore, identifying 
mechanisms by which PCB exposure can lead to such deleterious effects is 
relevant to public health. 
Environmental exposure to POPs such as PCBs is a major health 
concern, although subtly different from occupational exposure. The health effects 
from occupational exposures are more related to the smaller more metabolizable 
congeners and the subsequent formation of reactive potentially genotoxic 
metabolites. In contrast, the effects produced by the non-metabolizable PCBs in 
the body are expected to be chronic and life-long since they are not eliminated 
from the system. Aroclor 1260 production represented approximately 10.6% of 
total PCB production in the US between 1958-1977 which is modest compared to 
Aroclor 1242 (51.7%) (146). Nonetheless, Aroclor 1260 was selected for this 
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study because of the resemblance of congener composition pattern to that of 
human fat (36).  
Lipid-adjusted serum PCB levels were measured in NHANES participants 
and the PCB exposed Anniston cohort and reported to range from 75-170 ng/g 
(0.1 - 0.5 µM) (18, 46). Additionally, National Toxicology Program (NTP) studies 
reported the following PCB levels in a 2-year gavage study in rats: lipid-adjusted 
serum-4,650 ng/g; liver-64,593 ng/g; and adipose-2,495,994 ng/g (23). In these 
studies, PCB liver levels were at least 10-fold higher and PCB adipose levels 
were at least 200-fold higher than lipid-adjusted serum levels irrespective of the 
dose administered. In our experiments, we used Aroclor 1260 at concentrations 
ranging from 5-20 µg/mL (~10-50 µM) and selected congeners at 10 µM. These 
concentrations should approximate the range seen in bio-accumulated 
organs/tissues such as the liver and adipose tissue.  
Almost all PCB animal studies have been performed in rodents, where 
chronic toxicity is generally regarded as a function of the PCBs’ ability to interact 
with AhR and nuclear receptors. There are clear differences in the ligand affinity 
of these receptors, in rodents and humans, toward model ligands and xenobiotic 
compounds, including PCBs. In order to understand more clearly the involvement 
of PCBs in human NAFLD as demonstrated in human epidemiological studies 
such as NHANES, it is important to understand specific interactions between 
PCBs and human receptors. The findings from the current study demonstrate 
that Aroclor 1260 activates PXR (Fig. 4.3) and to a lesser extent AhR (Fig. 4.2), 
suggesting that congener composition is critical in determining a mixture’s 
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mode(s) of action. The effect of Aroclor 1260 on the AhR is likely due to the 
presence of coplanar congeners such as PCB 126. However, because these 
coplanar compounds are only a small fraction of this mixture, a higher 
concentration of Aroclor 1260 would be required to observe the “dioxin-like” 
effects. PCB 138, a non-coplanar congener, may also be responsible for the 
Aroclor 1260 effect on the AhR. Parkinson et al demonstrated that some di-ortho 
substituted PCBs can induce hepatic microsomal benzo[a]pyrene hydroxylase, 
consistent with AhR activation. Thus, coplanarity does not necessarily define 
“dioxin like” PCBs from “non-dioxin like” ones (147).  
The interaction between Aroclor 1260 and the AhR is further confirmed by 
the CYP1A1 induction at higher exposure levels in primary hepatocytes (Fig. 
4.10). The CYP1A1 induction by Aroclor 1260 however was much less than the 
1000-fold induction by the AhR ligand, BA. Furthermore, CD36, another AhR 
target gene was not induced by Aroclor 1260 vs. BA exposure in primary 
hepatocytes, further suggesting that a higher concentration of Aroclor 1260 may 
be required for “dioxin-like” effects. In contrast to AhR, Aroclor 1260 appears to 
be a relatively good human PXR agonist as observed through transient 
transfection assays and CYP3A4 induction in primary human hepatocytes. PXR 
is a transcription factor that plays a distinct role in drug metabolism and recent 
studies demonstrated its role in maintaining energy homeostasis in the body. 
PXR activation is associated with decreased expression of genes involved 
in lipid catabolism namely carnitine palmitoyltransferase-1a and 3-hydroxy-3-
methylglutaryl-CoA-synthase and increased expression of the lipogenic gene 
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stearoyl-CoA desaturase1 which could contribute to NAFLD (105). Exposure to 
PXR agonists also decreases blood glucose levels in fasting mice and this effect 
is related to forkhead box O1 (FoxO1) sequestration by PXR (74). A recent study 
by He et al. reported that ablation of this receptor in mice was protective against 
diet-induced and genetic obesity and improved insulin resistance (77). PXR 
activation clearly leads to disruption in the body’s energy balance and this may 
be one of the mechanisms through which PCBs exert their effects on hepatic 
energy metabolism. Using transient transfection assays, Tabb et al. 
demonstrated that highly chlorinated PCBs including PCBs 184 and 197 inhibited 
human PXR (148). However, PCB 184 is not a component of Aroclor 1260 and 
PCB 197 accounts for only 0.07% of its total congener composition. This 
concentration is not likely sufficient to inhibit human PXR. In our study, the 
majority of PCBs in Aroclor 1260 appear to be PXR agonists.  
As its name implies, wild type CAR is a constitutively active receptor due 
to a truncation that prevents internalization of the transactivation domain (AF2) 
and results in recruitment of co-activators. In vivo, CAR is regulated through its 
sequestration in the cytosol by chaperone proteins. Upon ligand binding, the 
receptor translocates to the nucleus and binds to its respective gene response 
elements. The cytosolic localization process is absent in immortalized cell lines. 
Consequently, performing transactivation studies in cell lines using in vitro 
reporter-based systems can be challenging due to the absence of ligand 
activation effect normally exhibited by CAR. However, in humans, the CAR 
transcript is spliced into several variants, in particular CAR2 and CAR3 that 
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constitute approximately one third of the CAR mRNA pool and encode functional 
CAR proteins (138, 140). Interestingly, both CAR2 and CAR3 splice variants 
have additional amino acids within the receptor’s ligand binding or 
heterodimerization domain that function to configure these variants as ligand-
activated receptors, unlike the parent CAR. Aroclor 1260’s interaction with 
human CAR is perhaps crucial, given the fact that non-coplanar PCBs, such as 
PCB 153, activate murine CAR target genes, including Cyp2b10. Of further 
interest, CAR has recently been identified as an anti-obesity nuclear receptor 
whose activation prevents obesity and improves type 2 diabetes through 
inhibition of lipogenesis and improved insulin sensitivity (72). 
A recent study by Al-Salman et al. demonstrated that non-coplanar PCBs, 
namely PCBs 153, 180 and 194, are agonists for the human PXR and CAR at 10 
µM (97). In that study, a receptor activation assay was performed in Huh7 cells 
using Checkmate mammalian two hybrid system where activated PXR/CAR bind 
to the DNA-binding domain of the NR Gal4 fusion plasmid. In the current 
investigation, we deployed a series of transactivation assays to evaluate the 
potential role of various PCB congeners to activate human CAR/PXR directly. In 
HepG2 cells, Aroclor 1260 activated CAR2 at 10 µg/mL but not at higher 
concentrations (Fig. 4.4). The mixed agonism/antagonism observed with CAR2 
appeared concentration-dependent with antagonism seen at higher 
concentrations. In additional studies conducted with COS-1 cells, the results 
obtained with CAR3 were particularly intriguing, in that several PCB congeners 
were identified as human CAR activators (Fig. 4.5), in particular, PCBs 187, 183, 
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149, 138, as well as Aroclor 1260 (ranked in decreasing order of potency). CAR3 
is likely a highly sensitive and reasonable surrogate for CAR1, based on previous 
reports that include modeling of the receptors’ ligand binding pockets (140, 149), 
whereas CAR2 appears to possess subtle alterations within its binding pocket 
that modify its ligand interaction profile compared with CAR1 (150). 
In other experiments, Aroclor 1260 exposure induced the CAR target 
gene, CYP2B6 in human hepatocytes, indicating that this agent acts primarily as 
a CAR activator and not antagonist. This result is consistent with the activation 
profile exhibited by Aroclor 1260 on human CAR3 in the transactivation assay. 
However, it should be noted that ligand binding to CAR is not the sole 
mechanism by which CAR is activated. Recently, Mutoh et al. reported that 
phenobarbital, a well-known CAR agonist, indirectly activated CAR by inhibiting 
the epidermal growth factor receptor signaling which subsequently 
dephosphorylated CAR and mediated its translocation into the nucleus (151). We 
anticipate that some of the PCB congeners may not directly interact with CAR, 
but may act through the same mechanism as phenobarbital. Further studies will 
be required to test this possibility.   
Previous studies showed that co-exposure to PCB 153 and high fat diet 
worsened NAFLD and obesity in male C57Bl/6 mice through upregulation of fatty 
acid synthase, an LXRα target gene (48). However in the current study, Aroclor 
1260 interacted with neither LXRα nor FXR. Although there was no direct effect 
by PCBs on either LXRα or FXR, we cannot rule out the possibility of an indirect 
interaction via cross-talk or alterations in nuclear receptor expression. However, 
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nuclear receptor cross-talk is complex and not well established especially in 
relation to PCBs. Therefore more studies are required to elaborate on the 
possibility of cross-talk. Aroclor 1260 did not activate PPARα but it antagonized 
PPARα activation by nafenopin at higher concentrations (Fig. 4.8). However, 
none of the congeners tested at 10 µM exhibited any antagonism. Robertson et 
al. reported the suppression of peroxisomal enzyme activities and CYP4A 
expression in male Sprague-Dawley rats treated with co-planar PCBs, including 
PCBs 77, 122, 126 and 169 (98). Considering the fact that Aroclor 1260 has a 
lesser percentage of coplanar PCBs than non-coplanar structural components, 
we may reconcile the possibility that a higher concentration of this PCB mixture 
may be required to antagonize PPARα whereas PPARγ remained unaffected.  
In summary, Aroclor 1260 is an activator of human PXR and CAR 2/3 
variants. It also appears to activate human AhR and to antagonize human 
PPARα at higher concentrations. The current study is clinically relevant because 
human receptor activation by a PCB mixture that simulates PCB bioaccumulation 
in humans was examined at relevant concentrations. Furthermore, the effects of 
PCBs on human nuclear receptors such as LXRα and FXR and in human 
hepatocytes have never been assessed before. Additionally, this is the first study 
to evaluate PCB activation on the CAR variants. Because PCB exposures have 
been associated with obesity, NAFLD and metabolic syndrome and these 
disorders are intimately involved with nuclear receptor activation, the results 







Overall goal and specific aims 
PCBs are persistent organic pollutants that dose-dependently increase the 
risk for liver injury as observed from epidemiologic studies. These poly-
halogenated compounds persist in the ecosystem and the heavily chlorinated 
congeners bio-accumulate in living organisms. As stated previously, the 
commercial PCB mixture, Aroclor 1260 has a congener composition 
representative of bio-accumulated PCBs. Aroclor 1260 was therefore chosen for 
this dissertation project to simulate human PCB exposure patterns. Furthermore, 
PCBs are predicted to interact with most receptors previously implicated in 
xenobiotic/energy metabolism and NAFLD. These receptors include the AhR, 
PXR, CAR, PPARs, LXRα and FXR. To determine if PCB exposure play a causal 
role in the development of NAFLD and steatohepatitis, and to gain insight into the 
mechanisms involved, the in vivo studies were undertaken using Aroclor 1260 at 
doses that correlated to human PCB body burden. The overall objective of the 
dissertation project was to evaluate the role of PCB exposure, using Aroclor 
1260, in fatty liver disease and to elucidate the potential PCB-receptor 
interactions that mediate fatty liver disease. To fulfill our objective, the following 
specific aims were proposed and carried out. 
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1A. Develop a mouse model for PCB exposure that simulates human 
exposure paradigms.  
1B. Evaluate the effects of the commercialized PCB mixture, Aroclor 1260, 
in obesity and NAFLD. 
2. Determine the role of the nuclear receptors, CAR and PXR, in liver 
injury caused by Aroclor 1260 and high fat diet co-exposure. 
3. Examine the interactions between Aroclor 1260/selected PCB 
congeners and human receptors in the liver 
Major findings of this dissertation 
The experiments described in Chapter 2, 3 and 4 addressed Specific Aim 
1, 2 and 3 respectively. The major findings from each Chapter are discussed in 
the following paragraphs. 
1. Evaluating the effects of Aroclor 1260 exposure in a diet-induced obesity 
mouse model 
Prior to initiating the animal studies, there were no documented studies on 
chronic HFD+PCB co-exposed animal models that simulate human exposure 
patterns. We therefore developed an animal model for studying the effects of 
PCB exposure at doses that were relevant to human exposure. Aroclor 1260 was 
administered to C57Bl/6 mice at 20 or 200 mg/kg via oral gavage in corn oil. The 
low dose (20 mg/kg) was designed to mimic the maximum human PCB 
exposures seen in the Anniston cohort and the high dose (200 mg/kg) was based 
on doses used in the NTP rodent carcinogenesis studies (18, 22).  
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It was observed that relevant doses of Aroclor 1260 along with HFD co-
exposure caused toxicant-associated steatohepatitis in a mouse model of diet-
induced obesity. In contrast to our previous study wherein a single congener 
(PCB 153) was used, this PCB mixture neither increased the body 
weight/visceral adiposity nor worsened insulin resistance/diet-induced obesity. 
On the contrary, Aroclor 1260 exposure was associated with decreased body fat 
in HFD-fed mice but had no effect on blood glucose/lipid levels. In fact, Aroclor 
1260 at higher doses appeared to reduce diet-induced obesity by decreasing the 
% increase in bodyweight gain (Fig. 2.2). Paradoxically, Aroclor 1260+HFD co-
exposed mice demonstrated increased inflammatory foci at both doses while the 
degree of steatosis did not change. Serum cytokines (Fig. 2.5) and hepatic 
expression of IL-6 and TNFα (Fig. 2.9) were increased only at 20 mg/kg, 
suggesting an inhibition of pro-inflammatory cytokine production at the 200 mg/kg 
exposure. Aroclor 1260 exposure induced hepatic expression of cytochrome 
P450s including Cyp3a11 (PXR target gene) and Cyp2b10 (CAR target gene) but 
Cyp2b10 inducibility was diminished with HFD-feeding (Fig. 2.10). Cyp1a2 (AhR 
target gene) was induced only at the higher dose (200 mg/kg). There was a 
significant difference between the low and high exposure doses in terms of 
hepatic/systemic inflammation, which could potentially be due to AhR activation. 
Aroclor 1260 activated CAR and PXR and to a lesser extent AhR, suggesting 
congener composition and exposure levels to be critical in determining a 
mixture’s mode(s) of actions. 
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2. Evaluating the role of CAR and PXR in liver injury caused by Aroclor 
1260 exposure in conjunction with HFD 
In Chapter 2, it was demonstrated that Aroclor 1260 at 20 and 200 mg/kg 
activated nuclear receptors CAR and PXR (152). In chapter 3, the role of CAR 
and PXR in Aroclor 1260+HFD-induced steatohepatitis was further evaluated. 
C57Bl/6 (WT), PXR knockout and CAR knockout mice were exposed to Aroclor 
1260 (20 mg/kg) and fed a high fat diet (42% kCal fat) for 12 weeks. Consistent 
with our previous findings, Aroclor 1260 exposure resulted in the transition of 
diet-induced steatosis to steatohepatitis and this was independent of the mouse 
genotype (Fig. 3.5). Basal hepatic TNFα expression was increased in the 
knockout groups independent of exposure (Fig. 3.6), indicating an anti-
inflammatory role of these receptors in NASH. Moreover, the PXR knockout mice 
had increased % body fat accompanied with decreased lean tissue mass and 
increased liver to body weight ratio, regardless of exposure (Fig. 3.1).  
An intriguing finding from this study was that Aroclor 1260 exposure 
decreased serum insulin levels and HOMA-IR in all groups (Fig. 3.8). This finding 
correlated with findings from the Anniston Community Health Survey studies 
where serum insulin decreased with increasing PCB body burden (153). This 
was a paradoxical finding, because PCB exposure was associated with diabetes 
in this population and diabetes is normally associated with an increase in HOMA-
IR, hence increased insulin levels and insulin resistance. The results suggested 
that PCBs may have an effect on insulin secretion and pancreatic function. 
Interestingly, a recent chronic exposure study using Aroclor 1254 reported 
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hyperinsulinemia in lean and diet-induced obese mice (49). However, the 
congener composition in Aroclor 1254 is strikingly different from that of Aroclor 
1260 (146), with the former containing higher amounts of dioxin like PCBs. 
Therefore, congener composition as well as the dose used may play a role in the 
observed hyperinsulinemia.  
The PXR knockout mice exposed to Aroclor 1260 showed a robust 
increase in hepatic gluconeogenic gene (PEPCK-1, G6Pase) expression (Fig. 
3.9), suggesting that PXR may be a major repressor of the gluconeogenic 
transcription factor, FOXO1. In terms of lipogenic gene expression, Aroclor 1260 
exposure decreased FAS and SCD1 mRNA levels in the WT group. However, 
the knockout groups had higher levels of basal FAS and SCD1 expression 
irrespective of Aroclor 1260 exposure (Fig. 3.11). This could be explained by the 
increase in basal mTOR1 activity in these groups as activated mTOR1 
corresponds to an increase in lipogenesis through nuclear localization of the 
lipogenic transcription factor, SREBP1 (113). On the other hand, Aroclor 1260 
exposure resulted in AMPKα activation which was consistent with an increase in 
hepatic expression of the glucose transporters (Fig. 3.13). AMPKα activation by 
Aroclor 1260 was manifested by the increase in RER in the knockout groups that 
were exposed to Aroclor 1260 (Fig. 3.3). Furthermore, both knockout groups 
demonstrated increased movement in the light cycle with Aroclor 1260 exposure, 
suggesting that this increase in physical activity may have driven AMPKα 
activation. However, the exact mechanism as to why Aroclor 1260 exposure 
caused hyperactivity in these animals remains to be investigated.  
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In summary, CAR and PXR activation appeared to be protective with 
regard to inflammation, lipogenesis and gluconeogenesis. However, CAR and 
PXR activation was not sufficient to protect the animals from developing NASH. 
This was possibly due to mechanisms independent of CAR and PXR activation 
such as compromised insulin levels and no improvement in obesity inspite of the 
improved leptin to adiponectin ratio. Moreover, the NASH symptoms that were 
observed in these animals such as insulin resistance and steatosis were 
uncoupled as compared to typical NASH hallmarks. We conclude that although 
CAR /PXR activation played a protective role in NASH induced by PCB+HFD, 
there are other receptor-based mechanisms responsible for the development of 
NASH that need to be addressed in this PCB/HFD model. 
3. Human receptor activation by Aroclor 1260 and selected individual PCB 
congeners 
 The studies in this Chapter evaluated Aroclor 1260 and selected 
congeners, as potential ligands for human receptors utilizing human hepatoma-
derived (HepG2) and primate-derived (COS-1) cell lines, and primary human 
hepatocytes. It is important to differentiate between rodent and human receptor 
activation because, although these receptors are highly conserved between 
species, some of these receptors such as the AhR vary in terms of ligand binding 
sites and target genes that they induce. The observed data suggested that 
Aroclor 1260 is a human AhR (Fig. 4.2), PXR (Fig. 4.3), a mixed 
agonist/antagonist for CAR2 (Fig. 4.4), a CAR3 agonist (Fig. 4.5) and an 
antagonist for human PPARα (Fig. 4.8). This study is clinically relevant because 
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human receptor activation by a PCB mixture that simulates PCB bioaccumulation 
in humans was examined at relevant concentrations. Furthermore, the effects of 
PCBs on human nuclear receptors such as LXRα and FXR and in human 
hepatocytes have never been assessed before. Additionally, this is the first study 
to evaluate PCB activation on the human CAR variants. Because epidemiologic 
studies have reported associations between PCB exposure and NAFLD, and 
since these disorders are intimately involved with nuclear receptor activation, the 
results clearly provide new insight into potential mode(s) of PCB action in human 
NAFLD.  
Strengths of this dissertation 
There is much strength in this dissertation. First and foremost, an animal 
model that simulated human PCB exposure patterns was developed. Secondly, 
we have identified steatohepatitis caused by PCB exposure in a diet-induced 
obesity mouse model and validated that the effects of a PCB mixture (Aroclor 
1260) vary from that of a single congener (PCB 153). The work has also provided 
insights in the underlying mechanism associated with PCB exposure such as 
dose- and diet-dependent activation of human and murine receptors including the 
AhR, CAR and PXR. Additionally, the results in this dissertation also answered 
key questions related to the role of CAR and PXR in hepatic energy metabolism 
and demonstrated the protective role of these receptors in PCB+HFD-induced 
liver injury.  
Another major strength of this dissertation includes the identification of 
PCB-mediated NASH effects that are dissociated from typical NASH hallmarks 
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such as the absence of insulin resistance. Furthermore, our observations of 
PCB-mediated NASH that resulted in a unique animal phenotype correlated with 
the observations seen in the PCB-exposed human population studies (153). 
Inspite of focusing on CAR and PXR, we have also distinguished other factors 
that play a role in PCB+HFD-induced liver injury such as the energy sensors, 
mTOR1 and AMPKα. The knockout studies demonstrated that chronic 
dysregulated receptor activation ensues in the PCB/HFD model that impact 
energy metabolism and liver injury. 
Limitations of this dissertation 
The primary limitation of this dissertation is that the hepatic and adipose 
concentrations of PCBs have not yet been quantified. This could potentially be 
done in the future using mass spectrophotometry. Quantifying the amount of 
PCBs in liver and fat will give us an idea of PCB compartmentalization in either a 
low fat diet or HFD setting.  Another limitation in the animal studies is that the 
pancreatic tissues were not harvested for analysis. Therefore, we failed to look at 
the effects of Aroclor 1260 exposure on pancreatic function and subsequently, 
insulin secretion. An additional caveat in the experimental design of the in vivo 
studies is that the mice received Aroclor 1260 either at a single exposure (20 
mg/kg) or four separate exposures (50 mg/kg) rather than the intermittent 
exposures that humans encounter from eating PCB- contaminated food. 
Furthermore, another drawback of this dissertation was using serum ALT/AST as 
a NASH biomarker based on low sensitivity, and evaluating other biomarkers is a 
possibility in future studies (50). In addition, for the knockout animal studies, a 
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2x2 ANOVA using SigmaPlot was used for statistical analysis. However, a more 
rigorous approach would be using the SAS/SPSS Programs to perform contrast 
and multiple correction tests and this will be accomplished in the near future. 
Lastly, all our in vivo studies were performed using male mice; hence it is 
pertinent to note that the observed effects may vary with gender and species, 
especially since PCBs may also modulate the estrogen receptor.   
Future directions 
Although the studies described in the dissertation have answered 
numerous questions related to the effects of PCB exposure on NAFLD and 
obesity, the research studies have also raised a number of questions that need 
to be addressed further.  Future research studies directed form this work are as 
follows: 
1. Evaluate the underlying mechanisms that resulted in decreased serum 
insulin levels with Aroclor 1260 exposure. 
The animal studies clearly pointed out that Aroclor 1260 exposure was 
associated with a decrease in serum insulin levels. However the exact 
mechanisms that led to decreased insulin levels were not evaluated in these 
studies. Insulin is synthesized within the β-cells of the Islets of Langerhans in the 
pancreas and its secretion is triggered by various stimuli including increased 
blood glucose levels (154). A 2-year study on a binary mixture of PCB 126 and 
PCB 153 by the NTP reported the development of pancreatic cancer in female 
SD rats (22). However, till date there are no studies reporting the effects of PCB 
exposure on pancreatic function, either in experimental animal models or in 
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epidemiologic studies. Therefore, the first logical step toward understanding the 
mechanisms behind the PCB-mediated decreased serum insulin levels is to 
examine the effects of PCB exposure on pancreatic structure and function.   
2. Define the direct vs. indirect PCB activation of CAR. 
In Chapter 2 and 3, we demonstrated that Aroclor 1260 exposure 
activated CAR by inducing its target gene, Cyp 2b10. CAR activation can occur 
either by direct binding to the receptor itself or indirectly through epidermal 
growth factor receptor (EGFR) signaling. Phenobarbital, a prototypical CAR 
ligand activates CAR indirectly by inhibiting the EGFR signaling which 
subsequently dephosphorylated CAR and mediated its translocation into the 
nucleus (151). We anticipate that some of the PCB congeners may not directly 
interact with CAR, but may act through the same mechanism as phenobarbital. 
Further studies will be required to test this possibility.  Interestingly, EGFR 
signaling promotes pancreatic β-cells expansion in response to a high nutrient 
state and in pregnancy (155, 156). It would be insightful to look at PCB-EGFR 
interactions since this may also answer questions related to the impact of PCB 
exposure on pancreatic function and insulin secretion.  
3. Investigate the effects of HFD feeding on CAR and PXR activation. 
Regardless of Aroclor 1260 exposure, it appeared that HFD consumption 
reduced the induction of CAR/PXR target genes as compared to CD 
consumption. HFD feeding reduced Cyp2b10 induction by approximately 235-
fold and 41-fold vs. CD feeding at 20 mg/kg and 200 mg/kg, respectively. These 
results appear consistent with previous studies (100, 101), and indicate that the 
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ability of CAR to activate target genes is compromised when animals are fed with 
HFD. We speculate that dietary components may interfere with CAR/PXR 
activation and therefore, it would be interesting to look at the effects of other diets 
such as high fructose diet. Another possibility is that the diet-induced steatosis 
may alter PCB compartmentalization and therefore PCB concentrations in the 
liver may vary, leading to lowered CAR/PXR target gene induction. 
4. Study the neurological effects of PCB exposure pertaining to physical 
activity. 
Because metabolic chamber studies indicated that Aroclor 1260 exposure 
increased movement in the knockout mice, it is worthwhile to study the PCB-
mediated effects in the brain. Studies have shown different PCB congeners 
interacting with the ryanodine receptor (157, 158), as well as dopamine and 
GABA neurotransmission (159, 160), and this could potentially impact motor 
activity. Although looking at PCB-mediated neurological effects is beyond the 
scope of an environmental liver disease laboratory, we can however collaborate 
with other groups that study PCB-mediated effects on the central and peripheral 
nervous system. 
5. Elucidate the role of the AhR in PCB+HFD-induced liver disease.  
The role of the AhR in steatosis and NAFLD has been investigated with 
studies showing that AhR activation is consistent with upregulated CD36 and 
SCD1 (110, 161). Using an AhR knockout or an AhR/CAR/PXR triple knockout 
mouse model will provide insight into the role of the AhR in our PCB/HFD mouse 
model. Another approach in this context is to use a binary mixture of Aroclors 
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such as Aroclor 1260 that has primarily non-dioxin like PCBs and Aroclor 1254 
that has mostly dioxin like PCBs. This will result in a PCB mixture that has 
approximately 15 to 30-fold more AhR activity than the one currently studied. 
6. Translate the animal findings to the PCB-exposed human population. 
The objective of this dissertation is to understand the role of PCB 
exposure in NAFLD, diabetes and obesity using animal models. We aim to 
translate our animal findings to the PCB-exposed human population so as to 
identify potential therapeutic targets that could be utilized to address the health 
disorders associated with this population. We will be using humanized AhR, CAR 
and PXR mice in our future studies to obtain data that is more relevant toward 
evaluating the PCB effects in humans. 
Conclusion 
Overall, Aroclor 1260 exposure resulted in the transition of steatosis to 
steatohepatitis in HFD-fed mice, thereby acting as a ‘second hit’ in diet-induced 
steatohepatitis. Aroclor 1260-induced NASH could involve activation of novel 
PCB receptors such as CAR and PXR or even non-receptor based modes of 
action. Both PXR and CAR are required to maximally attenuate Aroclor 1260-
induced changes in body composition, carbohydrate/lipid metabolism and 
inflammation in NASH. This is in stark contrast to hepatic steatosis induced by 
dioxin which is dependent on AhR activation (161). Also, CAR and PXR 
activation appeared to be protective in PCB-mediated toxicity but HFD 
consumption decreased the protective CAR/PXR activation, illustrating the 
importance of dietary co-exposures in PCB-related NASH (Fig. 5). Lastly, PCBs 
192 
 
also interact directly with human receptors, implicating the potential role of these 














Figure 5.1. Environmentally-relevant PCB-diet interactions mediate the 
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PROFESSIONAL MEMBERSHIPS 
2014-present Risk Assessment Specialty Section 
2013-present       American Society for Pharmacology & Experimental 
Therapeutics. 
2013-present       Molecular and Systems Biology Specialty Section 
2013-present Ohio Valley SOT Regional Chapter 
2013-present       Occupational and Public Health Specialty Section 
2013-present       Society of Toxicology. 
2012-present       Kentucky Academy of Science. 
237 
 
2009-2010       American Association of Pharmaceutical Scientists (AAPS) 
NIPER Student Chapter. 
 
PROFESSIONAL TRAINING AND DEVELOPMENT 
2014 
 
Completed CEd-Tox course “Basic Principles in Human Risk 
Assessment” 
2013       Grant Writing Academy, University of Louisville. 
2009      Online general course on Intellectual Property Rights, WIPO, 
Switzerland.    
 
LEADERSHIP 
2014 Member, Communications Subcommittee, GSLC, SOT. 
2014 Member, Graduate Student Leadership Committee, SOT. 
2014      Student Representative, Ohio Valley SOT Student Chapter. 
2012     Treasurer, American International Relations Club (AIRC), 
University of Louisville. 
2011      Public Relations Officer, AIRC, University of Louisville. 
2009      Secretary, Pharmaceutics Club, NIPER. 
 
AWARDS AND HONORS 
2014 Graduate Dean’s Citation 




2014 KC Huang Outstanding Graduate Student Award 2013 
2014 & 2012      Sponsored Research Tuition Award, School of 
Interdisciplinary and Graduate Studies, University of 
Louisville. 
2014 & 2013       Travel Award, Graduate School Council, University of 
Louisville. 
2013 Best PhD Platform Presentation, OVSOT Annual Meeting.
2013 Travel Award, School of Medicine Research Committee, 
University of Louisville. 
2011 Finalist, Research! Louisville Graduate Poster Session. 
2010-2012 Integrated Programs in Biomedical Sciences Fellowship 
2009      Runner up, Business Plan, 81MG, NIPER. 
2008 All India 119th Rank, General Aptitude Test in 
Engineering, IIS Bangalore, India. 
 
SERVICE: ACADEMIC AND COMMUNITY-RELATED 
2014 
 
Volunteer/Attendee, Midwest Membrane Trafficking & 
Signaling Symposium, Louisville. 
2014 
 
Proctor, Patient SIMS on Autonomics, School of Medicine, 
University of Louisville. 
2014 Organizer, OVSOT Annual Summer Student Meeting 
2014 Judge, Manual High School Science Fair. 
2013-present        Member, Golden Key International Honor Society, 
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University of Louisville. 
2013-summer    Volunteer, Children's Hospital Foundation, Kosair 
Children’s Hospital, Louisville, K.Y. 
2012-present        Member, University of Louisville Study Abroad. 
2011-present        Member, Indian Students Association, University of 
Louisville. 
2008-2006            Member, Indian Pharmaceutical Graduate Association 
(IPGA). 
 
 
 
 
 
 
 
